Graduate Theses, Dissertations, and Problem Reports
2020

Breast cancer associated muscle fatigue: Novel targets to
improve survival and quality of life
Hannah Elizabeth Wilson
West Virginia University, hewilson@mix.wvu.edu

Follow this and additional works at: https://researchrepository.wvu.edu/etd
Part of the Cancer Biology Commons

Recommended Citation
Wilson, Hannah Elizabeth, "Breast cancer associated muscle fatigue: Novel targets to improve survival
and quality of life" (2020). Graduate Theses, Dissertations, and Problem Reports. 7785.
https://researchrepository.wvu.edu/etd/7785

This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research
Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license
in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses,
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU.
For more information, please contact researchrepository@mail.wvu.edu.

i

Breast cancer associated muscle fatigue:
Novel targets to improve survival and quality of life
Hannah E. Wilson
Dissertation submitted
to the College of Medicine
at West Virginia University
in partial fulfillment of the requirements for the degree of
Doctor of Philosophy in
Cancer Cell Biology

Lori Hazlehurst, Ph.D., Chair
Wei Du, Ph.D.
John Hollander, Ph.D.
Malcolm Mattes, M.D.
Elena Pugacheva, Ph.D.
Emidio E. Pistilli, Ph.D., Advisor

Morgantown, West Virginia
2020

Keywords: breast cancer, cachexia, fatigue, patient-derived orthotopic xenograft,
peroxisome-proliferator activated receptors
Copyright 2020 Hannah E. Wilson

ii
ABSTRACT
Breast cancer associated muscle fatigue:
Novel targets to improve survival and quality of life
Hannah E. Wilson
Women diagnosed with breast cancer (BC) currently represent the largest group of
cancer survivors in the United States, accounting for over 20% of those living after a
cancer diagnosis. Most BC survivors report an unusual degree of fatigue, which can
present prior to diagnosis and continue for many years after treatment cessation.
Recent studies show that deficits in muscle function predict shorter survival in cancer,
perhaps due to the fact that fatigue is known to reduce a patient’s tolerance to anticancer therapies. Therefore, improving muscle function in BC patients has the potential
to improve both quality of life and survival in the most commonly diagnosed cancer type.
At present, few therapies for cancer-related fatigue show clinical efficacy, and the
pathogenesis of this condition is largely unknown. This work aimed to identify molecular
changes induced in skeletal muscle by BC, using patient samples and by developing
novel in vitro and in vivo model systems. We tested the hypothesis that BC induces
dysregulation of metabolic pathways regardless of molecular subtype or treatment
history. Transcriptomic and proteomic analyses in BC patient muscle samples indicated
mitochondrial dysfunction, which was evident across all molecular subtypes of BC and
unrelated to patients’ treatment histories. In vitro and in vivo experimentation confirmed
the ability of BC cells to alter mitochondrial respiration and ATP content in muscle tissue
via a secreted factor without the involvement of immune or stromal cell mediators.
These data indicate that BC-induced fatigue is related to defects in skeletal muscle
mitochondrial function induced directly by BC cells, and that targeting mitochondrial
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function or mitochondrial density in muscle could be a viable therapeutic strategy to
improve both survival and quality of life in BC survivors.
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CHAPTER 1: Literature Review
Breast cancer and cancer-related fatigue
Breast cancer (BC) is currently the most commonly diagnosed cancer in the United
States, affecting 1 in 8 women in their lifetime 1. Advances in BC treatment have led to
significant advances in overall survival in BC and other cancer types in recent decades
2, 3

, and 90% of women diagnosed with BC are now expected to live at least 5 years

after diagnosis 4. In many cases, cancer can now be thought of as a chronic disease
requiring long-term management, including addressing the numerous contributors to
diminished quality of life associated with this disease 5. One such contributor to
diminished quality of life in BC is the problem of cancer-related fatigue (CRF), which
affects the vast majority of women diagnosed with BC 6-9. CRF can present in BC
patients prior to the initiation of anti-cancer treatments 10, 11, is commonly exacerbated
by anti-cancer therapies 7, 9, 12, 13, and frequently affects women years after treatment
cessation 7, 9, 14. It is now established that deficits in muscle function are poor prognostic
indicators in cancer, perhaps because muscle atrophy and fatigue are known to reduce
a patient’s physical and psychological tolerance for anti-cancer therapies 9, 15-19.
Therefore, targeting muscle function in BC patients could improve both quality of life
and survival in BC, and this intervention would have the potential to impact millions of
women currently living with BC.
Management of CRF is a multifactorial endeavor due to the multifactorial nature of CRF.
Physicians are recommended to, to the best of their ability, identify the relative
contributors to CRF and target these factors individually 20. These contributory factors
include anemia, immunological responses to tumor growth or tumor cell death,
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hormonal and metabolic disturbances, and emotional distress, among other factors 20,
21

. Large scale interventional trials for CRF are severely lacking, likely due to the

multifactorial nature of CRF and the difficulty that complexity presents in identifying an
appropriate study population for a given intervention 20, 22. While several of the
contributory factors to CRF do have appropriate targeted therapies, such as selective
serotonin reuptake inhibitors for depression and iron supplementation for iron deficiency
anemia, CRF still remains an unmet need in clinical oncology according to patients
themselves. In fact, over 60% of respondents in a recent large-scale survey of patients
with cancer reported experiencing fatigue that they felt was not adequately addressed
by their medical providers 23. This disparity between symptom burden and therapeutic
options should be addressed to provide the ever-growing cadre of cancer survivors
longer and more enjoyable lives.
Cancer cachexia and its definitional ambiguity
The problem of cancer-associated cachexia, where individuals with cancer lose a
significant portion of their bodyweight and also experience a decline in physical function
12, 24

, has gained increasing attention in recent years. So much so that reversal of

cancer cachexia was named a “Provocative Question” by the National Cancer Institute
for 2020, a designation that confers additional funding avenues to researchers
addressing these questions 25. The exact definition of cancer cachexia has been in a
state of flux over the last twenty years. Most generally agree that for a person to be
cachectic, they must exhibit a significant degree of weight loss, and that weight loss
must not be simply due to decreased caloric intake and must be associated with a
disease 12, 24, 26. The recommended degree of weight loss required for a cachexia
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diagnosis varies among experts, and increasing evidence suggests that different
thresholds may be needed for different patient populations 27, though an international
group of clinicians and cancer cachexia researchers recently recommended 5% body
weight loss as the threshold for a cachexia diagnosis 24, 28. However, cachexia is not
only a weight loss syndrome; it also commonly culminates in metabolic abnormalities
and decline in physical function. This acknowledgment has led to experts calling for the
inclusion of functional and metabolic endpoints in interventional studies 29. Further, in
some clinical contexts, cachexia does not confer a survival deficit until 8% or even 10%
bodyweight loss has occurred, and conversely, weight-stable patients experiencing
cachexia-associated symptoms have decreased overall survival relative to other
patients 27, 30, 31. These data suggest that the definition of cachexia may need to be
specific for disease type or patient population, and that weight loss, sarcopenia, and
cachexia-related symptoms may need to be considered differently in different clinical
contexts. In general though, studies correlating overall survival with these various
definitions of cachexia unambiguously show that cachexia is a poor prognostic indicator
28

, with an even worse prognosis if patients are experiencing functional deficits or

severe weight loss 26, 31.
Cachexia presenting with advanced disease has been described by physicians for
millennia 32, but its mechanisms remain elusive and few therapeutic avenues have
exhibited clinical success 20. It is commonly assumed that deficits in skeletal muscle
function among individuals with cancer are caused by the muscle wasting observed in
cachexia, and therefore by preventing muscle wasting, muscle function will be
preserved. While this assumption is largely supported by data in men with cancer,
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women seem to exhibit a unique phenotype in that they can exhibit cancer-related
deficits in muscle function, including decreased strength and increased fatigability, in
the absence of muscle atrophy 33-36. This sexual dimorphism is important to
acknowledge for several reasons. First, clinicians should be aware that a woman may
be experiencing the symptoms associated with cachexia when she does not appear
frankly cachectic, with this being particularly important given that less than 5% of
women with BC have any cachexia-related International Classification of Disease code
in their electronic medical records 37. Additionally, it is unlikely that therapies focusing on
the maintenance or acquisition of muscle mass will be effective in reducing CRF in
women with cancer. And finally, studies addressing cancer cachexia and CFR should
study men and women separately given the obvious sexual dimorphism in physiological
responses to cancer. Many interventional studies in cancer cachexia have shown
negative results, but these may be related to problems with study design, specifically in
grouping men and women together 38-40, in grouping multiple cancer types together 38-41,
or in using only muscle mass or overall body weight as the primary endpoint without
also assessing muscle function 39, 42. Multiple large scale interventional studies have
reported improvements in muscle mass without concomitant improvements in muscle
functional parameters or quality of life scores, further emphasizing the need to assess
muscle function in addition to mass 43.
Animal models of cancer cachexia and cancer-related fatigue
Animal studies seeking to understand cancer-related fatigue exhibit similar issues in
study design. Because the definition of cachexia depends on the patient exhibiting
significant weight loss, all animal models used to study cancer cachexia exhibit this
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phenotype 44. Even many animal models developed with the express purpose of
studying cancer-related or treatment-related fatigue exhibit weight loss 45, 46. These
models are not appropriate for studying CRF in BC, where the majority of women
experience an unusual degree of fatigue despite remaining weight stable. Thus, a
significant goal of the work reported herein was the identification and study of a model
that adequately recapitulated the experience of BC patients, who describe an increased
susceptibility to fatigue in the absence of cachexia. To address this goal, we have
extensively characterized the muscle physiology response to BC in the patient-derived
orthotopic xenograft (PDOX) model, as the PDOX model has been previously shown to
reproduce human disease histology and progression better than cell line-based assays
47

.

Mechanisms of muscle fatigue
There are two major categories of mechanisms that contribute to pathological fatigue:
central fatigue, involving neural transmission within the brain and spinal cord, and
peripheral fatigue, which encompasses the actual motor units within muscle tissue, their
ability to respond to nervous stimulation, and factors that mediate this relationship such
as ATP availability and ion concentrations in various skeletal muscle compartments. It is
likely that both of these categories contribute to the fatigue experienced by women with
BC, but the scope of this research is limited to peripheral mechanisms of fatigue. These
include the coordinated transport of Na+ and K+ involved in cellular depolarization and
repolarization in response to nervous stimulation, release of Ca2+ from the sarcoplasmic
reticulum in response to membrane depolarization, calcium-dependent cross-bridge
cycling, ATP-dependent reuptake of Ca2+ back into the sarcoplasmic reticulum to allow
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for relaxation and succeeding contraction, and the metabolic processes that govern
high-energy phosphate availability, which is required for several of the aforementioned
activities. ATP availability is governed by several processes, including transfer of highenergy phosphate from phosphocreatine to AMP to form ATP in the creatine phosphate
shuttle system, generation of ATP in the tricarboxcylic acid cycle, and generation of
ATP by oxidative phosphorylation in the mitochondria. All of these activities have a
variety of regulatory mechanisms and therefore a multitude of factors can contribute to
ATP availability and therefore alter susceptibility to fatigue within skeletal muscle 48, let
alone the multitude of muscle-extrinsic factors that are beyond the scope of this project.
Muscle size is governed by a different but partially overlapping list of factors, but is
predominantly governed by the catabolism and anabolism of muscle structural
components in response to the contractile demands placed upon the muscle. Thus,
muscle disuse can lead to significant muscle atrophy, and this is frequently reported in
advanced disease where patients’ mobility is restricted. While the ability to carry out
activities of daily living can be impacted by both fatigue and muscle atrophy and fatigue
can lead to muscle disuse and subsequent atrophy, fatigue resistance is not related to
muscle size and therefore reversing muscle atrophy is unlikely to reverse the increased
susceptibility to fatigue experienced by BC patients. Further, ignoring the mechanisms
that contribute to fatigue while seeking to reverse atrophy may be counterproductive, as
fatigue can limit a patient’s ability to exercise and can therefore limit the contractile
stimuli required to induce muscle hypertrophy.

7
Peroxisome-proliferator activated receptors
The peroxisome-proliferator activated receptors are a family of lipid sensing, ligandactivated transcription factors that regulate multiple metabolic processes across
numerous tissue types. In particular, they play a large role in regulation of lipid
metabolism, with various isoform and tissue specificities. The PPARα isoform exhibits
higher expression levels in tissues with high rates of fatty acid catabolism, including the
liver, skeletal muscle, and cardiac muscle. The PPARγ isoform is largely specific for
adipose tissue, is considered a master regulator of adipogenesis, and modulates insulin
sensitivity, though low levels of expression are present in skeletal muscle 49. The
PPARγ isoform, in skeletal muscle in particular, likely plays a significant role in wholebody metabolic regulation because the muscle-specific PPARγ knockout mouse exhibits
marked insulin resistance, hyperlipidemia, hepatosteatosis, and increased fat mass
despite no difference in overall bodyweight relative to age-matched controls 50. The
PPARβ/δ isoform is not particularly well characterized despite being ubiquitously
expressed 49. It is apparent that this family of nuclear receptors aid in regulating whole
body energy homeostasis, and modulating these transcription factors pharmacologically
has significantly benefited patients with various metabolic diseases, including diabetes,
dyslipidemia, and atherosclerosis 51. Intriguingly, the use of PPAR agonists in preclinical mouse models of Lewis lung carcinoma 52, colon adenocarcinoma 53, and nonsmall cell lung cancer 54 has shown promising efficacy for cancer cachexia. Thus, it is
reasonable to suppose a mechanistic role for this family of transcription factors in the
metabolic derangements occurring in CRF, as well as in the treatment of this debilitating
syndrome.
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The present work
The work presented herein has focused on three major points. First, we aimed to
develop and characterize a mouse model that recapitulates the human BC phenotype of
increased muscle fatigability in the absence of muscle atrophy. Our identification of the
BC-PDOX model as such a model is a finding of paramount importance to the field, as it
will allow for focused investigation into this clinically common phenotype. We then
aimed to utilize the PDOX model to identify potential targetable mechanisms of muscle
fatigability using comparative transcriptomic analysis, utilizing muscle samples from
PDOX-bearing animals and women with BC and correlating gene expression changes
with patients’ clinical information. This avenue yielded several interesting target
pathways, with a leading candidate being dysregulation of mitochondrial function,
perhaps due to the apparent repression of PPAR signaling. Following up on this
potential target, we aimed to develop in vitro model systems for studying BC-induced
skeletal muscle dysfunction, choosing to utilize a conditioned media model. We have
been largely successful in developing such a model, showing that factors released from
BC cells induce significant metabolic changes in differentiated cultured muscle cells,
including repression of aerobic activity, induction of intramyocellular lipid accumulation,
and repression of PPAR-mediated transcription. Overexpression and pharmacological
modulation of PPAR-gamma significantly altered these phenotypes in skeletal muscle,
confirming that the PPAR signaling pathway is indeed linked to the mechanism by which
BC-derived factors produce metabolic changes in muscle cells. Overall, our data
support a paradigm of BC-induced fatigue resulting from skeletal muscle metabolic
dysfunction secondary to PPAR repression, suggesting that targeting mitochondrial
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function via the PPAR signaling pathway could be a viable therapeutic strategy to
improve BC-induced muscle fatigue.
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CHAPTER 2: Human breast cancer xenograft model implicates peroxisome proliferatoractivated receptor signaling as driver of cancer-induced muscle fatigue
This journal article describes the first animal model system to recapitulate the human
BC phenotype of increased muscle fatigability in the absence of muscle atrophy, using
the patient-derived orthotopic xenograft model of BC (BC-PDOX) 55. Here, we show that
the BC-PDOX model exhibits the expected phenotype of increased susceptibility to
fatigue in an ex vivo system without muscle atrophy, and we utilize RNA-sequencing
technology to compare transcriptomic changes occurring in muscle from BC patients to
those occurring in tumor-bearing animals. Using these technologies, we identify the
peroxisome-proliferator activated receptors as potential targets to treat BC-induced
muscle fatigue.
In this project, I conducted the majority of the bioinformatics and statistical analyses,
conducted all qRT-PCR and Western blotting experiments reported in the manuscript,
assisted with collection of muscle physiology data, and was the main contributor to the
manuscript text.

Published OnlineFirst December 17, 2018; DOI: 10.1158/1078-0432.CCR-18-1565
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Human Breast Cancer Xenograft Model Implicates
Peroxisome Proliferator–activated Receptor
Signaling as Driver of Cancer-induced Muscle
Fatigue
Hannah E. Wilson1,2, Kacey K. Rhodes2,3, Daniel Rodriguez4, Ikttesh Chahal5,
David A. Stanton5, Joseph Bohlen5, Mary Davis6, Aniello M. Infante7,
Hannah Hazard-Jenkins8, David J. Klinke9, Elena N. Pugacheva2,3, and
Emidio E. Pistilli2,5,9,10

Abstract
Purpose: This study tested the hypothesis that a patientderived orthotopic xenograft (PDOX) model would
recapitulate the common clinical phenomenon of breast
cancer–induced skeletal muscle (SkM) fatigue in the
absence of muscle wasting. This study additionally sought
to identify drivers of this condition to facilitate the development of therapeutic agents for patients with breast cancer
experiencing muscle fatigue.
Experimental Design: Eight female BC-PDOX–bearing
mice were produced via transplantation of tumor tissue from
8 female patients with breast cancer. Individual hind limb
muscles from BC-PDOX mice were isolated at euthanasia for
RNA-sequencing, gene and protein analyses, and an ex vivo
muscle contraction protocol to quantify tumor-induced aberrations in SkM function. Differentially expressed genes (DEG)
in the BC-PDOX mice relative to control mice were identiﬁed
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using DESeq2, and multiple bioinformatics platforms were
employed to contextualize the DEGs.
Results: We found that SkM from BC-PDOX–bearing mice
showed greater fatigability than control mice, despite no
differences in absolute muscle mass. PPAR, mTOR, IL6, IL1,
and several other signaling pathways were implicated in
the transcriptional changes observed in the BC-PDOX
SkM. Moreover, 3 independent in silico analyses identiﬁed
PPAR signaling as highly dysregulated in the SkM of both
BC-PDOX–bearing mice and human patients with early-stage
nonmetastatic breast cancer.
Conclusions: Collectively, these data demonstrate that
the BC-PDOX model recapitulates the expected breast cancer–induced SkM fatigue and further identify aberrant PPAR
signaling as an integral factor in the pathology of this
condition.

Introduction
Cachexia has been clinically recognized as a consequence of
advanced cancer for millennia (1) and has been recognized as a
cause of death in a signiﬁcant portion of patients with cancer for
nearly 100 years (2). Despite this long history, the mechanistic
underpinnings of this devastating condition remain poorly
understood, and no curative therapeutics exist (3). A complicating
factor in the treatment of cancer cachexia is its multifactorial
nature that deﬁes an easy deﬁnition, but most agree that cachexia
includes some combination of weight loss, inﬂammation, and
abnormal metabolism (4, 5). A multifactorial treatment approach
is needed to treat this syndrome (6–9), and that approach must
consider the potentially disparate pathologies contributing to
weight loss, muscle wasting, and muscle fatigue (10).
SkM dysfunction in patients with cancer is often considered a
consequence of muscle wasting. However, a large percentage of
women with breast cancer report fatigue (11–14) despite <20% of
patients with breast cancer experiencing signiﬁcant weight loss,
and <5% having any cachexia-related International Classiﬁcation
of Disease code on their electronic medical records (15). Although
muscle strength and fatigue are strongly related to muscle
mass in male patients with cancer, this does not appear to be the
case in women. Studies in multiple cancer types indicate female
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PDOX Model of Breast Cancer–induced Muscle Fatigue

Translational Relevance
Cancer-associated skeletal muscle fatigue is a common
problem in clinical oncology that is often associated with
cancer cachexia, but is not exclusively observed in cachectic
patients. The majority of patients with breast cancer report
muscle fatigue despite cachexia being relatively rare in this
patient population, especially in patients with nonmetastatic
disease. The clinically relevant phenotype of muscle fatigue in
the absence of frank cachexia has no established model system
and no approved therapeutic agents. Here, we utilize a breast
cancer patient-derived orthotopic xenograft (BC-PDOX) model to recapitulate the human phenotype of tumor-induced
muscle fatigue without muscle wasting. Bioinformatics analyses via multiple platforms identiﬁes PPAR signaling as central
to transcriptional alterations observed in skeletal muscle from
both BC-PDOX–bearing mice and human patients with breast
cancer. These data suggest that pharmacologic agents targeting
PPAR isoforms, such as FDA-approved thiazolidinediones
(TZDs), may be of clinical beneﬁt to patients with breast
cancer experiencing muscle fatigue.

patients with cancer lose muscle quality without losing muscle
mass (16–18). This sexual dimorphism in susceptibility to muscle
wasting versus muscle dysfunction must be acknowledged given
that women with advanced cancer have signiﬁcantly lower incidence of cachexia than men (19–21). One cannot conclude that
weight-stable women are immune to the quality-of-life deﬁcits of
cancer-induced muscle dysfunction. Elucidating the mechanistic
underpinnings of the clinically relevant phenotype of cancerinduced muscle dysfunction in female patients could provide a
great quality-of-life beneﬁt to patients with breast cancer and
survivors. A ﬁrst step toward this goal includes the establishment
of a model system that recapitulates the clinically relevant phenotype of cancer-induced muscle dysfunction in the absence of
muscle wasting.
A signiﬁcant barrier to progress in the ﬁeld of cancer cachexia is
the lack of a diverse set of model systems that adequately reﬂect
the heterogeneity of human responses to tumor growth. The use of
spontaneous or engrafted tumor models in inbred mouse strains
enforces a degree of uniformity in the laboratory that does not
exist in the clinic. Patient-derived orthotopic xenograft (PDOX)
models, wherein a human tumor fragment is implanted into the
appropriate anatomic location of an experimental animal, offer a
signiﬁcant improvement over established cell line–based grafts in
their increased ability to reproduce human disease histology and
progression (22). As the PDOX model recapitulates human disease histology, progression, and metastatic burden, it is reasonable to hypothesize that BC-PDOX mice will recapitulate the
common clinical phenomenon of breast cancer–induced SkM
fatigue in the absence of muscle wasting.
In this study, we characterized the transcriptional alterations
and assessed multiple physiologic parameters induced in SkM of
female mice bearing BC-PDOXs. RNA sequencing (RNA-seq) and
subsequent bioinformatics analyses indicated aberrations in
canonical pathways previously implicated in cancer cachexia,
along with multiple novel pathways that have not yet been related
to this phenomenon. Correlation of the BC-PDOX model with
our previously published gene expression proﬁle of SkM of

www.aacrjournals.org

human patients with breast cancer strongly implicates PPAR
signaling in the pathophysiology of breast cancer–induced muscle fatigue (23). To the authors' knowledge, this study represents
the ﬁrst characterization of cancer-induced alterations in the SkM
transcriptome in the context of a BC-PDOX model, as well as the
ﬁrst successful attempt to generate a model of breast cancer–
induced muscle dysfunction in the absence of muscle wasting.
Collectively, these data demonstrate that BC-PDOX tumor growth
recapitulates the expected breast cancer–induced muscle fatigue
and further identify aberrant PPAR signaling as an integral factor
in the pathology of this condition.

Materials and Methods
Patient selection
Breast cancer tumor tissue was procured at West Virginia
University (WVU) Cancer Institute (Morgantown, WV) and by
the NCI Cooperative Human Tissue Network under approved
WVU Institutional Review Board protocol and WVU Cancer
Institute Protocol Review and Monitoring Committee. Informed
written consent was obtained from each subject or each subject's
guardian. Individuals could be included in this study if they (i)
were deemed to have operable disease or were undergoing a
diagnostic biopsy, (ii) had been diagnosed with, or were suspected to have, invasive adenocarcinoma of the breast, (iii) were
over 21 years old, and (iv) provided informed consent. Muscle
biopsies were obtained from patients with breast cancer and
controls as previously reported (23). Conduct of research involving human patients at West Virginia University (Morgantown,
WV) is guided by the principles set forth in the Ethical Principles
and Guidelines for the Protection of Human Subjects of Research
(Belmont Report) and is performed in accordance with the
Department of Health and Human Services policy and regulations
at 45 CFR 46 (Common Rule).
Establishment of BC-PDOX models
Animal experiments were approved by the WVU Institutional
Animal Care and Use Committee. BC-PDOX models were produced by implanting freshly collected breast tumor tissue into
the cleared mammary fat pad of NOD.CG-Prkdscid Il2rgtm1 Wjl/SzJ/
0557 (NSG) mice (Fig. 1A) as described previously (24, 25).
Brieﬂy, female NSG mice were anesthetized with isoﬂurane. An
incision was made over the lower lateral abdominal wall, a 3-mm
pocket was opened under the skin to expose the mammary fat
pads, and a single tumor fragment of 2 mm3 was placed into the
pocket. Tumor growth was assessed by veterinary staff based on
approved WVU Tumor Development and Monitoring Policy.
BC-PDOX–bearing mice were euthanized by CO2 asphyxiation
upon reaching a maximal tumor burden score, or earlier if
exhibiting signs of health distress. BC-PDOX tumors were then
removed from the passage number 0 (P0) animals and cut into
fragments, which were then frozen and, in part, passaged into
na€ve NSG animals to produce passage number 1 (P1) PDOX.
Experimental animals bearing BC-PDOX (P0-2) were euthanized
at the same humane endpoint as P0 animals. Mice were housed at
22 C under a 12-hour light/12-hour dark cycle and received food
and water ad libitum. Each BC-PDOX model produced was authenticated with original patient's biopsy using genomic DNA and
short tandem repeat–based PCR ampliﬁcation (Arizona University Genomics Core Facility, Tucson, AZ). Routine human and
mouse pathogen screening was performed on original and
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Figure 1.
Establishment of BC-PDOX model. Analysis of SkM from BC-PDOX mice compared with NSG controls indicates widespread transcriptional reprogramming of
SkM transcriptome in response to tumor growth. A, Schematic diagram outlining establishment of BC-PDOX models (P0) and passaging of tumor to generate
study animals (P0-P2). B, Normalized gene expression heatmap showing differential expression patterns of the 50 most differentially expressed genes between
BC-PDOX (n ¼ 4) and NSG control mice (n ¼ 4) organized according to unsupervised clustering analysis. C, Principal component analysis showing that
transcriptional proﬁles of NSG and BC-PDOX SkM cluster separately, indicating that tumor growth induces transcriptional alterations in SkM.

passaged tissue by Charles River Laboratories. RNA sequence and
whole-exome analysis of original biopsy and passage 1 BC-PDOX
further conﬁrm relatedness of samples and stability of genomic
alterations identiﬁed in patient with breast cancer and corresponding PDOX. Expression of clinically relevant breast cancer
receptors correlate with the original breast cancer biopsy.
BC-PDOX mice (n ¼ 8) were compared with nontumor NSG
mice (n ¼ 6) as well as NSG mice that received human breast
cancer-PDOXs that did not engraft (PDOX-Con; n ¼ 5).

the study included uninjected control mice (Con; n ¼ 8), mice
euthanized following 2 weeks of tumor growth (2WK, n ¼ 5),
and mice euthanized following 4 weeks of tumor growth (4WK,
n ¼ 11). E0771 cells were obtained through an MTA (Wake Forest
University Health Sciences; July 2014). Cells were authenticated
and screened for the presence of contaminants prior to use
(IDEXX Bioresearch). Experiments described in this publication
using E0771 cells were completed between January 2015 and
June 2016.

E0771 syngeneic mammary tumor model
Detailed methods for E0771 mouse mammary tumor cell
growth in syngeneic C57BL/6 mice have been described previously (23). Brieﬂy, 1  106 E0771 cells were suspended in sterile
PBS and orthotopically implanted into the fourth inguinal mammary fat pad on the left side of experimental mice. Three arms of

RNA isolation, sequencing, and bioinformatics
Total RNA was isolated from gastrocnemius muscles of experimental mice (n ¼ 4/group) and pectoralis major muscles from
human patients (23) using TRIzol (Thermo Fisher Scientiﬁc) and
established methods (26). RNA purity was assessed using a
NanoDrop spectrophotometer, with 260/280 readings of at least
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2.0. RNA quantity was measured via a qubit ﬂuorometer. RNA
integrity was measured on an Agilent bioanalyzer with an RNA
Nano chip. RNA samples had RNA Integrity Numbers (RIN) >9,
indicating high-quality RNA. Libraries for RNA-seq were constructed and DEGs were identiﬁed according to previously published methods (23). RNA-Seq libraries were built using the
Stranded mRNA kit from KAPA Biosciences with Illumina compatible adapters. The concentrations of the completed libraries
were quantiﬁed with a qubit ﬂuorometer using high-sensitivity
DNA reagent. Libraries were subsequently run on the bioanalyzer
using a high-sensitivity DNA chip to determine average fragment
size. Completed libraries were then pooled in equimolar concentrations and sequenced on 1 lane of the HiSeq 1500 with
PE50 bp reads (BioProject ID: PRJNA496042; murine samples).
Subsequently, data were compared with the GRCm38.84 reference genome from Ensembl. There was no alignment step utilized. However, Salmon was used for quantiﬁcation, with both
gcBias and seqBias set, and libType A (27). Salmon output was
imported into DESeq using tximport (28). DESeq was run with
default parameters with the exception of a ﬁltering step: genes
which did not have a least 3 samples with a count of at least 10 were
eliminated. RNA-Seq output was analyzed using various bioinformatics platforms: STRING (29), Enrichr (30), Ingenuity Pathway
Analysis (IPA; Qiagen Inc., https://www.qiagenbioinformatics.com/
products/ingenuity-pathway-analysis/), and GeneAnalytics (31).
Values presented from Enrichr analyses represent those obtained
via querying the intersecting set of transcription factors' target
genes identiﬁed by both the Encyclopedia of DNA Elements
(ENCODE) and ChIP Enrichment Analysis (ChEA).
Protein isolation
Protein homogenates were made from tibialis anterior muscles
of experimental mice (n ¼ 4 or 5/group), pectoralis major muscles
from human patients with breast cancer (n ¼ 15), and control
female patients undergoing breast surgery (n ¼ 5) using a 5-mL
Wheaton Tissue Grinder (DWK Life Sciences Inc.) in a tissue lysis
buffer (20 mmol/L Tris HCl (pH ¼ 7.4), 150 mmol/L NaF,
1 mmol/L EDTA, 1% Triton X-100, 10% glycerol, 1 mmol/L
NaO3V) with 1 Pierce Protease and Phosphatase Inhibitor
(Thermo Fisher Scientiﬁc). Homogenates were cleared via brief
centrifugation, and protein concentration was quantiﬁed using
Pierce Coomassie Plus Protein Assay (Thermo Fisher Scientiﬁc)
according to the manufacturer's protocol.
Western blotting analysis
Protein homogenates were diluted to a ﬁnal concentration of
1 mg mL1 in 1X NuPAGE LDS Sample Buffer (Thermo Fisher
Scientiﬁc). Fifteen to 20 mg of total protein was loaded per well,
resolved in NuPAGE Novex 4%–12% Bis-Tris Gels (Thermo
Fisher Scientiﬁc). Proteins were transferred to nitrocellulose membrane, blocked for 1 hour in 1 TBS, 0.1% Tween20, 5% BSA
followed by incubation with primary antibody overnight at 4 C.
Membranes were then washed thrice in TBS þ 0.1% Tween20
prior to application of appropriate secondary antibody (Thermo
Fisher Scientiﬁc) for 90 minutes at room temperature, and again
prior to application of Pierce ECL Western Blotting Substrate
(Thermo Fisher Scientiﬁc). Relative band intensity was quantiﬁed
using the GE Amersham Imager 600 (GE Healthcare Life Sciences)
and normalized to GAPDH. Primary antibodies included the
following: phospho-Stat5 (#9314S; RRID: AB_2302702), phospho-Stat3 (#9138S; RRID: AB_331261), Stat5 (#9363S; RRID:
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AB_2196923), Stat3 (#9139S; RRID: AB_331757), PPARg
(#PA3–821A; RRID: AB_2166056), and GAPDH (#2118S; RRID:
AB_561053).
qRT-PCR
Total RNA was isolated from gastrocnemius muscles of
BC-PDOX mice (n ¼ 8), NSG control mice (n ¼ 6), PDOX-Con
mice (n ¼ 5), and pectoralis major muscles of patients with breast
cancer (n ¼ 20), and control female patients (n ¼ 10) as described
above. Two mg of cDNA was produced using Invitrogen SuperScript III First-Strand Synthesis System (Thermo Fisher Scientiﬁc)
according to the manufacturer's protocol, and relative expression
of selected genes was analyzed using SYBR Green PCR Master Mix
(Thermo Fisher Scientiﬁc) with the Applied Biosystems 7500
Real-Time PCR System (Thermo Fisher Scientiﬁc). Primer efﬁciencies were determined to be between 90% and 110%,
and relative mRNA expression was calculated using the Pfafﬂ
method (32). qRT-PCR primers (Supplementary Table S1) were
designed using Primer3 (33).
Ex vivo muscle physiologic analysis
Muscle contractile properties were examined in the extensor
digitorum longus (EDL) muscles of experimental mice using
methods as described previously (34–36). Muscles were transferred to an oxygenated tissue bath containing Ringer solution
(100 mmol/L NaCl, 4.7 mmol/L KCl, 3.4 mmol/L CaCl2,
1.2 mmol/L KH2PO4, 1.2 mmol/L MgSO4, 25 mmol/L HEPES,
and 5.5 mmol/L D-glucose) maintained at 22 C. Muscle length
was adjusted to obtain the maximal twitch response and this
length was recorded as optimal length (i.e., Lo). Parameters
analyzed from isometric twitch contractions included peak
isometric twitch force (Pt), contraction time (CT), 1/2 relaxation
time (1/2 RT), rate of force production, and rate of relaxation. With
the muscle set at Lo, the force–frequency relationship was generated to quantify maximal force by stimulating muscles with
increasing frequencies as follows: 1, 5, 10, 25, 50, 80, 100, 120,
and 150 Hz. Muscle fatigue was analyzed using a repeated
stimulation protocol lasting 6 minutes and consisting of repeated 40 Hz tetanic trains that occurred once every second and
lasted 330 ms. LabChart software V7 (AD Instruments, RRID:
SCR_001620) was used to obtain the area under the fatigue curve
(AUC) and used as a measure of total force produced during
the fatigue protocol. To interpolate the fatigue data as a function
of time, a piece-wise cubic spline function with 5 evenly spaced
interior knots was linearly regressed to the data using the splines
(V3.4.0), spline2 (V0.2.8), and stats (V3.4.0) packages in R
(V3.4.0; RRID: SCR_001905). The ﬁrst derivative of the ﬁt cubic
splines and the corresponding 95th percentile conﬁdence intervals were used to determine whether the rate of change in fatigue
was signiﬁcantly different between conditions. Muscle cross-sectional area (CSA) was calculated by dividing the muscle mass by
the product of the muscle density coefﬁcient (1.06 g. cm3), muscle
Lo, and the ﬁber length coefﬁcient (EDL: 0.45). The calculated
whole-muscle CSA value was used to calculate speciﬁc force (i.e.,
absolute force mN. muscle CSA–1; refs. 37, 38).
Statistical analysis
GraphPad Prism (V5; RRID: SCR_002798) was utilized to
analyze the following datasets. Student t test was used (a ¼
0.05) to compare means for protein expression via Western
blotting and log2-transformed fold changes [log2 (FC)] in mRNA
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expression in human samples. One-way ANOVA was used to
compare log2 (FC) in mRNA expression in murine samples,
muscle weights, and selected muscle contractile properties,
including AUC, Lo, isometric force, CT, 1/2 RT, rate of force
production, and rate of relaxation. Two-way ANOVA was used
to compare differences between groups in force output over time
during the 6-minute fatigue protocol. Goodness-of-ﬁt (r2) for
the relationship between STAT3 and STAT5 activation (e.g.,
pSTAT3/total STAT3) versus each physiologic parameter was
analyzed using the linear regression feature of GraphPad Prism,
comparing the best-ﬁt linear regression line to H0 where the bestﬁt line is a horizontal line (i.e., m ¼ 0) through the mean of all
Y values (n ¼ 8, pooled NSG and BC-PDOX).

Results
In silico pathway and transcription factor analysis of RNA-Seq in
skeletal muscles from the BC-PDOX mouse model
Muscle tissue from 4 mice bearing unique BC-PDOX tumors
representing 4 different patients were used for RNA-Seq (Supplementary Table S2) and compared with muscle tissue from nontumor NSG control mice. Unsupervised clustering analysis identiﬁed a unique transcriptional signature present in the BC-PDOX
muscle, with a general trend of transcriptional downregulation
(Fig. 1B), supporting our previously published transcriptional
signature of SkM from early-stage patients with breast cancer (23).
Principal component analysis (PCA) shows clustering of the
BC-PDOX SkM transcriptional signatures, separate from the more
tightly clustered controls (Fig. 1C).
IPA identiﬁed several canonical pathways as being dysregulated in this model, with multiple identiﬁed pathways having
been previously implicated in cancer cachexia and muscle
dysfunction in other models, including signaling via PPARs,
mTOR, IL1, and IL6. IPA additionally identiﬁed several pathways that have not yet been connected to cancer cachexia and
therefore warrant further study in the context of tumor-induced
SkM dysfunction, such as integrin and gap junctions signaling.
Interestingly, IPA predicted no signiﬁcant dysregulation within
3 pathways that have been strongly implicated in cancer
cachexia in other models (Fig. 2A). IPA molecule activity
predictor (MAP) predicted inhibition of muscle contraction
resulting from aberrant calcium release from the sarcoplasmic
reticulum (Fig. 2B). MAP additionally predicted decreased ATP
generation in SkM due to decreased activity of electron transport chain complexes IV and V (Fig. 2C).
The observed trend of transcriptional downregulation in
both patients with breast cancer (23) and the BC-PDOX SkM
transcriptomes suggests the involvement of genome-wide transcriptional reprogramming. We therefore conducted an in silico
transcription factor–enrichment analysis of the downregulated
transcripts in each model (Fig. 2D), as well as an analysis including all DEGs (Supplementary Fig. S1A and S1B) using Enrichr.
This analysis identiﬁed PPAR gamma (PPARg) and nuclear
factor (erythroid-derived 2)–like 2 (NFE2L2, also known as
NRF2) as transcriptional regulators with altered activity in both
models. Consistent with this analysis, NFE2L2/NRF2 and PPAR
signaling were also identiﬁed as dysregulated by IPA (Fig. 2A). IPA
predicted weak inhibition of STAT3 and moderate inhibition of
STAT5 signaling in the BC-PDOX SkM relative to NSG control
mice (Fig. 2E). Contrary to previous reports on the involvement
of STAT3 in tumor-induced SkM dysfunction (39), IPA, Enrichr, or
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conﬁrmatory Western blotting did not identify signiﬁcant activation of STAT3 in SkM in our model (Supplementary Fig. S1A–C).
Interestingly, we observed a near-signiﬁcant increase in pSTAT3
and total STAT3, and a statistically signiﬁcant decrease in total
STAT5 (Supplementary Fig. S1D and S1E), but no signiﬁcant
change in the ratio of activated to total STAT protein in either
case, suggesting alternative signaling might be involved. In addition, the ratio of activated to total STAT3 or STAT5 protein did
not correlate with any muscle contractile parameter obtained
(Supplementary Table S3).
Comparison of RNA-Seq proﬁles in skeletal muscles from
human patients with breast cancer and BC-PDOX mice
identiﬁes PPAR-signaling as a central regulator of breast
tumor–associated transcriptional alterations in muscle tissue
In comparing the SkM-speciﬁc gene expression signatures from
the BC-PDOX model with the previously published transcriptome
of SkM of human patients with breast cancer (23), expression of
40 transcripts were similarly altered, with 85% of these being
downregulated in both models (Fig. 3A). STRING analysis identiﬁed a signiﬁcant functional relationship between the 40 input
genes (P ¼ 4.87e14), with PPAR signaling molecules being
central to the generated network and insulin signaling molecules
as enriched in the 40-gene set (Fig. 3B). Given that 40 genes is a
somewhat undersized dataset for enrichment analysis, we utilized
2 additional bioinformatics tools to verify the role of PPARg as
a regulator of mammary tumor–induced SkM alterations. Consistent with our transcription factor analysis of downregulated
transcripts in each model (Fig. 2), in silico transcription factor
analysis of the 40 overlapping DEGs identiﬁed PPARg as the
single signiﬁcantly enriched transcriptional regulator (adjusted
P ¼ 4.8e6; Fig. 3C). A third gene enrichment tool, GeneAnalytics,
also identiﬁed PPAR signaling, twice, in the 8 high-scoring pathways enriched in the 40-gene set (Fig. 3D), where high-scoring
matches are deﬁned as those with a corrected P < 0.001 when
using a binomial distribution to test the null hypothesis that
the 40 input genes are not overrepresented in the pathways noted
on the x-axis. Negative controls for Enrichr and STRING enrichment analyses using a random set of 40 protein-coding genes
identiﬁed no signiﬁcant enrichments, with all adjusted P > 0.9
(Supplementary Fig. S1F and S1G).
Veriﬁcation and validation of RNA-Seq proﬁles in skeletal
muscles from BC-PDOX mice and human patients with breast
cancer
The gene expression of Pparg and a subset of known and
predicted Pparg targets identiﬁed in Fig. 3A (Cidec, Fabp4, Rbp4,
Slc1a5) were veriﬁed and validated by qRT-PCR in the same
samples used in RNA-Seq as well as in a new cohort of
SkM samples, respectively. In muscles from the original cohort
of BC-PDOX mice, the median log2 (FC) was negative for all
genes, indicating downregulation of gene expression. In the
veriﬁcation samples, Cidec, Pparg, Rbp4, and Slc1a5 were significantly downregulated. In the validation samples, Fabp4 was
signiﬁcantly downregulated, and Cidec and Pparg showed a statistical trend for downregulation (Fig. 4A). In muscles from
human patients with breast cancer, the median log2 (FC) was
negative for all samples, indicating downregulation of gene
expression. In the veriﬁcation samples, Fabp4, Pparg, Rbp4, and
Slc1a5 were signiﬁcantly downregulated, whereas Cidec showed a
statistical trend for downregulation. In the validation samples,
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Figure 2.
In silico pathway and transcription factor analysis of RNA-Seq data. A, Selected canonical pathways identiﬁed by IPA in the transcriptome of BC-PDOX mice. For
each pathway listed on the x-axis, the y-axis reports the raw number of differentially expressed genes in the BC-PDOX SkM relative to NSG controls, separated
into up- and downregulated transcripts. The y-axis additionally reports the –log (P) reported by IPA; –log (P) > 1.33 is equivalent to P < 0.05. The ﬁgure reports
pathways identiﬁed by IPA as signiﬁcantly dysregulated in our model that have been previously implicated in cancer cachexia (left), signiﬁcantly dysregulated in
our model but not previously implicated in cancer cachexia (center), or previously implicated in cancer cachexia but not identiﬁed by IPA as signiﬁcantly
dysregulated in our model (right). B, IPA predicts decreased release of calcium from the sarcoplasmic reticulum in the SkM of BC-PDOX mice resulting in
decreased muscle contraction. C, Complex IV and V of the electron transport chain are predicted by IPA to have decreased activity in the BC-PDOX mice relative
to NSG controls, resulting in decreased ATP production. D, Top ten most highly ranked transcriptional regulators identiﬁed by Enrichr as regulating the
transcriptional alterations observed in SkM of BC-PDOX and human patients with breast cancer where the input gene list was exclusively downregulated
transcripts. Transcription factors are ranked by overlap% (calculated as [(transcripts regulated by transcription factor x) \ (transcripts differentially expressed in
SkM of tumor-bearing subject)]/(transcripts regulated by transcription factor x). The y-axis reports overlap%, –log (adjusted P), and combined scores for each
transcription factor as reported by Enrichr. Arrows identify PPARG and NFE2L2/NRF2. E, IPA upstream regulator analytic predicts weak inhibition of STAT3. Key
for (B, C, E): green shading indicates decreased expression of transcripts coding for the shaded entity, red shading indicates increased expression of transcripts
coding for the shaded entity, blue shading indicates decreased predicted activity/production of the shaded entity, and orange shading indicates increased
predicted activity/production of the shaded entity.

Pparg and Slc1a5 were signiﬁcantly downregulated, whereas Cidec
and Fabp4 showed a statistical trend for downregulation (Fig. 4B).
The protein abundance of PPARg was evaluated in muscles from
patients with breast cancer. Although there were no differences in
total PPARg protein between control and patients with breast
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cancer, we did observe a greater abundance of a truncated form of
PPARg, at approximately 40 kDa, in the muscles from patients
with breast cancer (Fig. 4C). Following orthotopic implantation
of the syngeneic mouse breast tumor cell line, E0771, Pparg gene
expression in SkM was lower in weight-stable tumor-bearing mice
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Figure 3.
Genes with altered expression in patients with breast cancer and BC-PDOX mice identiﬁes PPAR signaling as potential driver of breast cancer–induced SkM
Fatigue. A, Venn diagram identifying 40 genes with commonly altered expression (e.g., downregulated in both sets) in both human patients with breast cancer
and BC-PDOX mice, with experimentally veriﬁed targets of PPARs underlined. B, STRING in silico protein–protein interaction analysis identiﬁes signiﬁcant
functional interactions between the 40 commonly altered transcripts (P ¼ 4.87e-14), with PPARg and related signaling molecules central to the generated
network of protein–protein interactions present in the set of 40 commonly altered transcripts (red, KEGG 03320, FDR ¼ 0.003). Insulin signaling molecules are
also signiﬁcantly enriched in this gene set (blue, KEGG 04910, FDR ¼ 0.018). C, PPAR signaling is identiﬁed by GeneAnalytics twice in the eight pathways
identiﬁed as high-scoring matches (corrected P < 0.0001). D, Enrichr in silico transcription factor analysis (ENCODE and ChEA Consensus from ChIP-X) identiﬁed
PPARg as the single signiﬁcantly enriched transcriptional regulator in the 40 commonly altered transcripts. The y-axis reports overlap%, –log (adjusted P), and
combined scores for each transcription factor as reported by Enrichr; log(adjusted P) > 1.33 is equivalent to adjusted P < 0.05.

and was greater in tumor-bearing mice that lost body weight
(Supplementary Fig. S2).
Tumor growth in BC-PDOX mice induces a greater rate of
skeletal muscle fatigue and a slowing of isometric contractile
properties
EDL muscles from BC-PDOX–bearing mice, NSG control mice,
and PDOX-Con mice were stimulated ex vivo using a repeated
contraction protocol to analyze muscle fatigue properties in
response to BC-PDOX growth. The shape of the fatigue index
curve from muscles of BC-PDOX mice was signiﬁcantly different
than the curve from NSG control mice and PDOX-Con mice,
especially during the ﬁrst 80s of the protocol, with force output
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declining rapidly from the initiation of the protocol (Fig. 5A).
AUC was also signiﬁcantly lower in muscles from BC-PDOX mice
compared with muscles from NSG control mice and showed a
statistical trend when compared with muscles from PDOX-Con
mice (Fig. 5B). These fatigue responses in mice implanted with
BC-PDOXs are strikingly similar to the muscle fatigue responses
we previously reported in an orthotopic syngeneic breast cancer
model using C57BL/6 mice (23). Fatigue data were also interpolated as a function of time to evaluate the rate of change in muscle
fatigue during different phases of the fatigue protocol (Fig. 5C).
The rate of change was signiﬁcantly greater in muscles from
BC-PDOX mice compared with muscles from both control
groups during the early phase of the fatigue protocol (i.e., ﬁrst
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Figure 4.
qRT-PCR and protein veriﬁcation and validation of RNA-Seq. qRT-PCR was performed for Pparg and a subset of known and predicted Pparg target genes to both
verify and validate the RNA-Seq completed in muscles from BC-PDOX mice and human patients with breast cancer. A, Veriﬁcation and validation of RNA-Seq in
muscle samples from control and BC-PDOX mice. B, Veriﬁcation and validation of RNA-Seq in muscle samples from control and patients with breast cancer. Each
graph includes the log2 (FC) and associated P value for the gene analyzed. C, Protein quantiﬁcation of PPARg in muscle samples from control (n ¼ 5) and patients
with breast cancer (n ¼ 15). One representative blot is presented.  , P < 0.05.

150 contractions). Thus, muscles from tumor-bearing mice have a
greater rate of fatigue and reach their threshold force values earlier
in the fatigue protocol. Similar rate of change curves were
obtained in EDL muscles from immunocompetent C57BL/6 mice
following 4 weeks of orthotopic E0771 mammary tumor growth
(Supplementary Fig. S3A). These data demonstrate a greater rate
of muscle fatigue in response to mammary tumor growth regardless of the host's immune status, providing strong support for an
effect of mammary tumor growth on inducing muscle fatigue.
Isometric contractile data for the EDL muscles in all groups are
presented in Table 1. Although there was no signiﬁcant difference
in CT, the rate of force development of twitch contractions was
lower in muscles from BC-PDOX mice. In addition, 1/2 RT was
longer and the rate of relaxation was lower in EDL muscles from
BC-PDOX mice. Similar contractile properties were observed in
EDL muscles from mice bearing syngeneic E0771 mammary
tumors (Supplementary Fig. S3B). Absolute twitch and tetanic
forces were lower in muscles from BC-PDOX mice. However,
speciﬁc twitch and tetanic forces were not different between
groups. There were no signiﬁcant differences in the absolute
mass of EDL, soleus, gastrocnemius, or tibialis anterior muscles
among the groups (Fig. 5D). Collectively, these data indicate
that isometric twitch properties of the fast EDL muscle are
slowed in response to mammary tumor growth in the absence
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of quantiﬁable differences in muscle mass and normalized isometric force output.

Discussion
This study tested the hypothesis that the BC-PDOX mouse
model would recapitulate the common clinical phenomenon of
breast cancer–induced SkM fatigue in the absence of muscle
wasting. We found that BC-PDOX–bearing mice indeed show
greater SkM fatigability than nontumor-bearing NSG control
mice and PDOX-Con mice, despite no differences in absolute
muscle mass. We then discovered that SkM from BC-PDOX–
bearing mice exhibits widespread transcriptional changes, including alterations in pathways previously reported to be relevant to
cancer cachexia (e.g., PPAR, mTOR, IL6, IL1) as well as those that
have never been reported in this condition (e.g., signaling
via integrins and gap junctions). These data validate the use of
BC-PDOX as a model of breast cancer–induced SkM dysfunction
and identify novel therapeutic targets to improve muscle function
in patients with breast cancer.
We have recently published the unique transcriptional signature of SkM from patients with early-stage nonmetastatic breast
cancer, which showed transcriptional alterations in pathways
involved in mitochondrial function, oxidative phosphorylation,
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Figure 5.
BC-PDOX induces SkM fatigue. A, Average ex vivo SkM fatigue curves generated for NSG control animals (NSG, n ¼ 6), surgical control animals (PDOX-CON,
n ¼ 5), and BC-PDOX mice (n ¼ 6), using the EDL muscle. The leftward shift of the BC-PDOX fatigue curve indicates greater fatigability. The chart presents mean
fatigue index  SEM for every 10th contraction in the fatigue protocol; PDOX-CON versus PDOX groups compared via 2-way ANOVA. B, AUC for the fatigue
curves presented in A. C, First-derivative curves generated for the fatigue curves presented in A, representing the rate of change in force output of the EDL
muscle. D, Absolute mass comparisons of EDL, soleus, gastrocnemius, and tibialis anterior muscles in the BC-PDOX mice, NSG mice, and PDOX-CON, showing
no signiﬁcant differences;  , P < 0.05;   , P < 0.01,    , P < 0.001; means compared via 1-way ANOVA unless otherwise stated.

and PPAR signaling (23). These data revealed that SkM responds
to breast tumor growth with a general downregulation of transcriptional activity; a response that was not affected by breast
tumor subtype or whether patients received chemotherapy prior
to surgery and biopsy acquisition. In addition, the gene networks
identiﬁed were dysregulated in SkM at a time when cachexia (i.e.,
muscle wasting) was likely not evident, as both body mass index
and serum albumin levels were not different between patients

with breast cancer and patients without breast cancer in this
study (23). In this study, we extend these observations by analyzing a cohort of immunocompromised mice bearing human
breast cancer tumors of multiple molecular subtypes, including
luminal, triple-negative, and HER2-overexpressing tumors. When
comparing the transcriptional signature of SkM in human patients
with breast cancer with SkM from BC-PDOX mice, similar patterns
emerged with respect to affected markers and pathways, with

Table 1. Ex vivo isometric contractile parameters in the EDL muscle
EDL Lo (mm)
Twitch (mN)
Twitch (mNCSA1)
Contraction time (ms)
1
/2 Relaxation time (ms)
Rate of force development (mNs1)
Rate of relaxation (mNs1)
Tetanus (mN)
Tetanus (mNCSA1)

2344 Clin Cancer Res; 25(7) April 1, 2019

NSG
11.5  0.4
38.5  4.4
40.4  19.6
21.4  6.9
31.7  4.1
1,481  339.3
682.3  46.2
201.1  22.5
204.3  85.2

BC-PDOX
11.8  0.4
33.3  7.9
34.4  8.1
25.0  5.5
46.0  5.5
1,038  180.1
450.9  174.2
179.6  41.3
184.6  40.9

PDOX-Con
11.1  1.1
51.9  7.1
44.6  8.1
23.0  9.5
33.3 7.1
1,867  415.2
921.5  169.5
243.7  28.0
212.8  33.3

P
0.0985
0.0001
0.3178
0.7220
0.0017
0.0010
0.0001
0.0015
0.6233
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40 genes concordantly affected by breast tumor growth in SkM
from human patients with breast cancer and mice bearing human
breast tumors. This set of 40 genes represents those that are
dysregulated early in the course of breast cancer progression
(patients with breast cancer), remain dysregulated into the late
stages of disease (BC-PDOX model), and are altered in 2 different
SkMs (pectoralis major vs. gastrocnemius). Moreover, our in silico
analysis strongly implicates PPAR signaling in the transcriptional
alterations observed in SkM in response to tumor growth, and a
large percentage of the DEGs common to both BC-PDOX and
breast cancer patients' SkM are either veriﬁed or predicted targets
of PPARs. A subset of these PPAR targets, including Cidec, Fabp4,
Rbp4, and Slc1a5 are central to the network of protein–protein
interactions present in the SkM of both patients with breast
cancer and BC-PDOX mice and were validated and veriﬁed in
both mouse and human muscle samples. Therefore, it is probable
that these genes and their associated networks represent a significant driving force behind breast cancer–induced muscle dysfunction and fatigue and further suggest that PPAR signaling may
be mechanistically central to breast cancer–associated SkM dysfunction. Although Pparg gene expression was downregulated in
muscles of human patients with breast cancer, we did not observe
a concomitant reduction in PPARg protein abundance. However,
our PPARg antibody did recognize a lower molecular weight
(40 kDa) protein with a greater abundance in muscles from
patients with breast cancer. Studies have suggested that truncated
forms of PPARg, which are cleaved by active caspases, decrease
the transcriptional activity of PPARg by not translocating to the
nucleus (40–42). This mechanism of action is consistent with
our analyses, in which multiple downstream targets of PPARg
are transcriptionally downregulated in muscles of patients with
breast cancer and BC-PDOX mice.
PPARs are lipid-sensing, ligand-activated transcription factors
that regulate multiple metabolic processes throughout the body,
with a particularly strong role in regulation of glucose and lipid
metabolism. PPARa is predominantly expressed in tissues with
high rates of fatty acid catabolism, including liver, SkM, and
cardiac muscle. PPARg is highly expressed in adipose tissue, is
considered a master regulator of adipogenesis, and modulates
insulin sensitivity. PPARb/d is the least well-characterized of the
PPARs, but it is ubiquitously expressed in most tissues, regulates
blood cholesterol and glucose levels, and is involved in fatty acid
oxidation (43). Because PPARs play an obvious role in regulating
whole body energy homeostasis, there has been signiﬁcant success
in modulating these transcription factors for the beneﬁt of
patients with diabetes, dyslipidemia, and atherosclerosis (44);
and promising anticatabolic efﬁcacy has been observed with
PPAR agonists in mouse models of Lewis lung carcinoma (45),
colon adenocarcinoma (46), and non–small-cell lung cancer
(47). PPARg is 1 of the main regulators of adipocyte differentiation (48, 49) and is downregulated in SkM of patients with breast
cancer (23) and BC-PDOX–bearing mice. Clinical trials utilizing
PPARg agonists have been undertaken for breast cancer previously, as there was a hypothesis that the agonists would cause the
mammary tumor cells to undergo terminal differentiation and
cease proliferation (50, 51). A phase II trial using the oral antidiabetic drug and PPARg ligand troglitazone in patients with
advanced breast cancer showed no beneﬁt in terms of breast
cancer progression, but this study did not report assessments of
body weight, muscle strength, or muscle fatigue. The drug was
tolerated well by patients (52), however. As our data indicate that
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downregulation of PPARg transcriptional activity may play an
important role in mediating breast cancer–associated muscle
dysfunction, further studies assessing the efﬁcacy of PPARg agonists in ameliorating breast cancer–induced fatigue are warranted.
BC-PDOX tumor growth in female mice resulted in increased
SkM fatigability, decreased rate of force development, decreased
rate of twitch relaxation, and increased 1/2 RT in the fast EDL
muscle. This shift to a slower, more fatigable EDL occurred despite
no change in EDL mass relative to control mice. The rate of twitch
force development and relaxation are both strongly inﬂuenced by
calcium release and reuptake in specialized compartments of the
myocyte. The rate of force development in SkM depends upon the
rate of calcium release from the sarcoplasmic reticulum (SR)
through the ryanodine receptors (RyR), and the rate of SkM
relaxation is strongly inﬂuenced by the removal of calcium ions
from the cytoplasm by the sarco/endoplasmic reticulum Ca2þ
ATPase (SERCA; refs. 53, 54). Expression of multiple key regulators of calcium ﬂow in SkM were altered, and IPA identiﬁed
canonical calcium signaling pathways as being signiﬁcantly
altered in the BC-PDOX SkM. Expression of transcripts encoding
calsequestrin 1 (casq1), calsequestrin 2 (casq2), and RyR were all
decreased, and IPA predicted impaired calcium release from the
SR as a direct result of these transcriptional alterations, which may
explain the slowed rate of force development in BC-PDOX SkM.
However, we did not observe a change in mRNA expression of
any SERCA isoform (adjusted P values of 0.64, 0.87, and 0.92
for Atp2a1, Atp2a2, and Atp2a3, respectively). Our data directly
conﬂict with recent reports describing increased expression of
calsequestrin (39) and SERCA isoforms (39, 55) in SkM of tumorbearing mice. This discrepancy could reﬂect differences in the
animal models used, cancer types studied, or stage of cancer
cachexia progression.
A recent report quantifying SkM deﬁcits in male APCMin/þ
mice during cachexia progression similarly identiﬁed a slower,
more fatigable phenotype in the SkM of weight-stable mice,
with STAT3 activation correlating with alterations in the rate of
twitch contraction and relaxation (39). In our BC-PDOX model,
we observed alterations in the rate of twitch contraction and
relaxation in the absence of STAT3 activation, and STAT3 activation did not correlate with any muscle contractile parameter
obtained from the BC-PDOX mice. This discrepancy indicates
that while inﬂammation correlates with the slowing of SkM
physiology in 1 model, inﬂammatory signaling via STAT3 is likely
not associated with the slowed muscle contractile parameters
observed in BC-PDOX mice.
Collectively, our data show that breast cancer–induced muscle
dysfunction can be effectively recapitulated and studied in a
BC-PDOX model. The overall slowing and greater rate of fatigue
of the fast EDL muscle, coupled with altered expression of several
key regulators of SkM calcium handling, suggest that alterations in
calcium handling contribute to the slow, fatigable phenotype
induced by tumor growth. In addition, 3 independent in silico
analyses identiﬁed PPARg signaling as highly dysregulated in both
BC-PDOX SkM and in the muscle of patients with early-stage
breast cancer, suggesting that PPAR agonists may be of clinical
beneﬁt to patients with breast cancer experiencing fatigue. In
conclusion, PPAR signaling, particularly PPARg signaling, likely
mediates a signiﬁcant portion of mammary tumor's impact on
SkM. Further studies are warranted to determine whether PPAR
agonists would provide a quality-of-life beneﬁt to patients with
breast cancer with muscle dysfunction. Given that the side effect
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proﬁle of these drugs is relatively benign, PPAR agonists may
prove useful as an additive therapy to alleviate cancer-induced
muscle fatigue.
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CHAPTER 3: Skeletal muscle reprogramming by breast cancer regardless of treatment
history or tumor molecular subtype
This article represents an extension of the findings presented in Chapter 2 to include an
analysis of transcriptomic and proteomic changes in skeletal muscle from patients with
all major molecular subtypes of BC, as well as an analysis of clinical parameters
governing muscle’s molecular response to BC. We report that patients with all molecular
subtypes of BC exhibit similar pathway-level dysregulation in their skeletal muscle, with
the common alterations indicating significant disruptions in metabolism of
carbohydrates, protein, and lipids. These alterations do not appear to be related to prior
treatments, as treatment-naïve individuals exhibit similar changes to patients who
underwent neoadjuvant therapies.
In this project, I conducted the majority of bioinformatics and statistical analyses, carried
out all Western blots, created the HEK-PPRE reporter cell line, completed most of the in
vitro assays, and was the main contributor to the manuscript text.
This article is currently undergoing major revisions with npj Breast Cancer as of April 10,
2020.
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ABSTRACT
Increased susceptibility to fatigue is a negative predictor of survival commonly
experienced by women with breast cancer. Here, we sought to identify molecular
changes induced in human skeletal muscle by BC regardless of treatment history or
tumor molecular subtype using RNA-sequencing (RNA-seq) and proteomic analyses.
Mitochondrial dysfunction was apparent across all molecular subtypes, with the greatest
degree of transcriptomic changes occurring in women with HER2/neu-overexpressing
tumors, though muscle from patients of all subtypes exhibited similar pathway-level
dysregulation. Interestingly, we found no relationship between anti-cancer treatments
and muscle gene expression, suggesting that fatigue is a product of BC per se rather
than clinical history. In vitro and in vivo experimentation confirmed the ability of BC cells
to alter mitochondrial function and ATP content in muscle. These data suggest that
interventions supporting muscle in the presence of BC-induced mitochondrial
dysfunction may alleviate fatigue and improve the lives of women with BC.
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INTRODUCTION
Muscle dysfunction in individuals with cancer is commonly thought to be a consequence
of muscle atrophy, which is a major component of the paraneoplastic syndrome known
as cancer cachexia 1,2. While studies in men with cancer support the claim that muscle
functional capacity is dependent on muscle size, women with cancer report a significant
degree of muscle dysfunction despite typically remaining weight-stable 3-5. Muscle
dysfunction in breast cancer (BC) commonly presents as a persistent, severe fatigue
that frequently contributes to dose reduction or treatment cessation and is an
independent predictor of survival in a variety of cancer types, including BC 6-11. Thus, it
is probable that improving muscle fatigue will improve both quality of life and survival in
BC.
At present, there are several purported contributory factors for cancer-related fatigue,
including immunological responses to tumor growth; side-effects of cancer therapies;
depression and/or emotional distress; anemia; hormonal, nutritional, and metabolic
disturbances; and inadequate physical activity 8,12. Pharmacological treatments for
cancer-related fatigue exhibit limited and inconsistent success, in part because
determining the mechanisms contributing to fatigue in a given patient can be quite
challenging, particularly in patients with early-stage disease and those not receiving
anti-cancer treatments 13. Identifying mechanisms of BC-related fatigue that are intrinsic
to skeletal muscle, generalizable across BC subtypes, and independent of treatment
status could significantly aid in the development of appropriate therapies, which would
be applicable to a large number of patients experiencing BC-associated fatigue.
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Our laboratory has recently reported that skeletal muscle of women with BC exhibits a
distinct gene expression signature that is not dependent on molecular subtype 14.
Furthermore, we have identified signaling via the metabolic regulators of the
peroxisome-proliferator activated receptor (PPAR) family as potential key mediators of
fatigue in women with BC and female mice bearing BC patient-derived orthotopic
xenografts (PDOXs) 15. Our previous analyses did not include women with primary
tumors that overexpressed HER2/neu in the absence of estrogen receptor (ER) and
progesterone receptor (PR) expression. In the current study, we have expanded our
analyses into all molecular subtypes, including both transcriptomic and proteomic
analyses of muscle biopsies from patients with HER2/neu-overexpressing tumors, and
significantly increased our sample size to create, to our knowledge, the largest study of
transcriptomic and proteomic changes in muscle of women with BC. We tested the
hypothesis that BC induces a common molecular response in skeletal muscle that is
independent of the molecular subtype of the tumor and the patient’s treatment history.
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RESULTS
Patient characteristics. A total of 51 BC patients representing 4 breast tumor subtypes
and 20 non-cancer controls provided pectoralis major muscle biopsies and/or detailed
clinical information for use in the present study. There were no differences in mean
body mass index (BMI) between non-cancer controls and BC patients; average BMI in
the control group was categorized as Class I Obesity and in the BC patients was
categorized as Overweight. Additionally, there were no significant differences in the
percent (%) change in BMI, body fat %, or lean body mass between controls and BC
patients. There were no differences in BMI between any of the 4 breast tumor subtypes
(Table 1).
Skeletal muscle gene expression profiles. Skeletal muscle biopsies from patients
diagnosed with BC (n=33) and non-cancer controls (n=10) were used for RNA-seq, and
BC patients were classified based on molecular subtype of their primary tumor, as
follows: luminal (ERPR)— positive for estrogen receptor (ER) and progesterone
receptor (PR) without overexpression of HER2/neu; HER2 —overexpression of
HER2/neu in the absence of ER and PR expression; triple negative (TN)—absence of
ER, PR, and HER2/neu expression; and triple positive (TP)— presence of ER and PR
expression, and overexpression of HER2/neu (ERPR n=10, HER2 n=5, TN n=9, TP
n=9). Unnormalized gene expression counts are provided for each sample
(Supplemental Table 1). Unsupervised clustering and principal component analyses
suggested the possibility of clustering based on molecular subtype, particularly with
regard to patients with tumors overexpressing HER2/neu in the absence of ER or PR
(Figure 1A). Multidimensional scaling (MDS) analysis restricted to 3 dimensions
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revealed that the gene expression profiles of skeletal muscle from patients with ERPR,
TP and TN tumors were similar, while the profile from skeletal muscles from patients
with HER2/neu-overexpressing tumors was significantly different (Figure 1B). Overall fit
of the MDS model was dramatically improved by the use of BC subtype as a covariate
(Figure 1B, adjusted R2=0.44, p=0.0001) rather than a model including only binary
disease status (Figure 1C, adjusted R2=0.20, p=0.008), which was already a significant
improvement over the null model (Figure 1D).

To address the question of whether this obvious difference in overall muscular gene
expression between groups was inherent to differences in the primary tumor type or the
myriad of clinical characteristics that could potentially differ between groups, we
assessed the relationship between clinical characteristics and skeletal muscle gene
expression in the context of a multivariate linear regression model, using the 3
dimensions of the MDS dissimilarity matrix as response variables. Among the various
treatment types, body composition, serum albumin, and changes in body mass, the only
assessed variable to yield statistical significance at α=0.05 when used as a single
independent variable was patient group (i.e. Control, ERPR, HER2, TN, TP), with serum
albumin nearing statistical significance (Table 2). Notably, chemotherapy, radiotherapy,
and hormonal treatments did not correlate with overall gene expression patterns, nor did
the patient’s trend of weight change over time. Using forward selection, a final model
including patient group and serum albumin was identified as the best-fitting model for
predicting muscular gene expression from clinical data (Table 3).
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Because serum albumin appeared to provide predictive value for skeletal muscle gene
expression data, and because serum albumin is commonly used by oncologists to
monitor patients’ nutritional status, the relationship between serum albumin and
changes in BMI over time were assessed in the group of patients that provided biopsies.
There was no correlation observed between serum albumin at the date of biopsy
collection and the individual’s rate of weight change over time (Figure2A). Similar
results were obtained in a retrospective chart review of 3,001 patients with BC. While
there was a statistically significant correlation between a patient’s first record of serum
albumin and the patient’s rate of weight change in this large sample (Figure 2B), the
effect size may well be clinically insignificant (R = 0.094). The average daily weight
change was negligible in women with normal serum albumin as well as those with low
serum albumin (< 3.4 g · dL-1), with both groups having means within one standard
deviation of 0 (Figure 2C). For a patient to be considered cachectic by traditional
standards, an average daily weight loss of at least 0.027% would be required to lose 5%
of their weight in 6 months 1,2. In our large cohort, a logistic regression analysis was
conducted using a threshold of 3.4 g · dL-1 serum albumin to predict whether a patient
would exhibit this rate of weight change. In this analysis, omnibus model fit was
significant at ɑ < 0.05, though effect size as determined by
Nagelkerke’s pseudo-R2 was very small and indicates a very weak predictive value (R2
= 0.08). Additionally, a threshold of 3.4 g · dL-1 serum albumin was only 40% sensitive to
identifying this level of weight change and only yielded a positive predictive value of
17.3%. In other words, 60% of BC patients exhibiting a rate of weight loss consistent
with cachexia had normal serum albumin, while BC patients with serum albumin < 3.4 g
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· dL-1 only had a 17.3% chance of exhibiting a rate of weight change consistent with
cachexia.
Differential gene expression analysis by subtype. Differentially expressed genes
(DEGs) within skeletal muscle were first identified by comparing BC patients by subtype
to control. Considerable overlap of DEGs was observed between the 4 breast tumor
subtypes. Of the 3,468 genes identified as differentially expressed in at least one
subtype, only 7 (0.2%) were unique to ERPR patients, 173 (5.0%) to TN patients, and
80 (2.3%) to TP patients. However, 2,410 genes (70%) were unique to HER2 patients,
and only 8 (0.23%) were differentially expressed in all patient groups (Figures 3A and
3B). These observations were quantified and reveal that there was an approximately 2fold fewer-than-expected number of unique DEGs in muscle of patients with ERPR, TP
and TN tumors if the DEGs were independent of subtype. Specifically, one would
expect 14, 186, and 508 unique DEGs in each subtype, respectively, whereas we
actually observed 7, 80, and 173 DEGs in these groups. Further, HER2 patients’ muscle
exhibited 2-fold fewer-than-expected DEGs shared with any combination of two other
subtypes (Observed = 5 + 2 + 84 = 91; Expected total = 203; overall χ2 on 6 degrees of
freedom = 1224, p = 3 x 10-261). This indicates that the ERPR, TP, and TN groups share
a greater number of DEGs in skeletal muscle than one would expect if the DEGs were
independent of subtype and in contrast, muscle from HER2 patients does not exhibit the
same similarity to the other subtypes in terms of shared DEGs (Figure 3C). Collectively,
these data demonstrate that transcriptional responses in skeletal muscle of patients with
ERPR, TP and TN tumors are highly similar, in support of previous data from our
laboratory 14,15. Furthermore, the transcriptional responses in muscles from patients with
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HER2/neu-overexpressing tumors partially overlap with the other subtypes, but exhibit a
significant contrast to the other 3 subtypes, suggesting that this tumor type is associated
with a unique transcriptional adaptation within skeletal muscle.
Pathway analysis by subtype. The Broad Institute’s Gene Set Enrichment Analysis
(GSEA) tool 16 was used to infer pathway-level dysregulation based on trends in
transcriptomic changes, assessing all pathways in the Kyoto Encyclopedia of Genes
and Genomes (KEGG) 17. Identified pathways were shared between all breast tumor
subtypes to a greater extent than individual genes. Of the 70 pathways identified as
dysregulated in any subtype, 19 (27.1%) pathways were identified as significantly
dysregulated in all 4 breast tumor subtypes relative to control. 2 (2.9%) pathways were
uniquely dysregulated in muscle from patients with TP tumors, 10 (14.2%) in patients
with ERPR tumors, 7 (10.0%) unique to TN patients, and 4 (5.7%) uniquely
dysregulated in patients with HER2/neu-overexpressing tumors (Figures 4A, 4B, 4C).
Chi-square analysis to test whether the number of pathways shared between subtypes
differed between groups was non-significant (overall χ2 on 6 degrees of freedom = 3.67,
p = 0.72), indicating that the four BC subtypes share a common core of dysregulated
pathways (Figure 4C). The 19 overlapping pathways clearly show a substantial degree
of metabolic alteration, including pathways involved in carbohydrate, lipid, and protein
metabolism (Figure 4D). While the enrichment of Alzheimer’s, Parkinson’s, and
Huntington’s diseases may seem unusual, these pathways include a large number of
mitochondrial genes, explaining why these pathways cluster with Oxidative
Phosphorylation. The enrichment of the KEGG Peroxisome pathway is significant, as
our laboratory has previously identified the PPAR proteins as likely upstream regulators
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of muscle fatigue in BC 14,15. Though our multivariate linear regression model did not
show neoadjuvant therapies to predict overall gene expression, the upregulation of
transcripts in the KEGG p53 signaling pathway is likely a response to chemotherapy
and/or radiotherapy.

HER2 patient proteomics. Because the HER2 patient group exhibited the greatest
degree of transcriptomic dysregulation, muscle biopsies from these patients (n=5) were
selected for proteomic analysis and compared to control surgical patients (n=5).
Unnormalized protein abundance estimates are provided for each sample
(Supplemental Table 2). Scaled, log-transformed expression data from proteomic
analyses were correlated with scaled, log-transformed RNA-seq expression data in a
gene-wise fashion. 8/8 individuals with matched RNA-seq and proteomic analyses were
found to have moderately strong correlation (Pearson’s R range 0.48 – 0.52,
Supplemental Figure 1). A total of 1,555 unique proteins were detected across all
samples, 1,259 of those at a high confidence level, with most proteins being detected in
all 10 samples (Figure 5A). Differential expression analysis detected only a small
number of significantly differentially expressed proteins (FDR < 0.05, Figure 5B),
though there are obvious physiological implications in the small set. The six
downregulated differentially expressed proteins (DEPs) were all identified as
mitochondrial components (Figure 5C), representing a statistically significant
enrichment of mitochondrial components in this small set of DEPs (Figure 5D, p = 3.2 x
10-6). Expanding our analysis to both significant DEPs and insignificant trends in protein
expression, a strong signal for aberrant mitochondrial function was once again
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detected. Nearly every protein involved in the mitochondrial electron transport chain
was quantified as having a lower level of protein expression in the HER2 patients
relative to controls (Figure 5E, Supplemental Table 3), including proteins encoded by
both nuclear DNA and mitochondrial DNA. GSEA results from the proteomic data were
highly similar to those obtained in the RNA-seq analysis (Supplemental Figure 2), with
significantly affected pathways including Oxidative Phosphorylation (NES = -2.97, FDR
< 0.001), Citrate Cycle (NES = -2.12, FDR < 0.001), Peroxisome (NES = -1.71, FDR =
0.02), and Fatty Acid Metabolism (NES = -1.66, FDR = 0.27), among other pathways.
Two mitochondrial proteins identified as significantly differentially expressed in the
HER2 patient group were selected for validation by Western blotting in a completely
independent cohort of patients, without regard to patient molecular subtype. Both
proteins assessed were confirmed to have lower abundance in the BC group compared
to control (Figure 5F).

Subtype-independent DEG analysis and experimental validation. To cross-validate
our RNA-seq GSEA results using an independent software, pathway-level enrichment
analysis was conducted using the list of genes that were significantly differentially
expressed when comparing all BC patients to control (FDR < 0.10). In this analysis, we
observed a strong signal indicating aberrant mitochondrial function across multiple
databases queried. For example, three of the top four enriched pathways identified
when querying the WikiPathways 2019 Human database included Electron Transport
Chain System in Mitochondria (WP111), Oxidative Phosphorylation (WP623), and
Mitochondrial Complex I Assembly (WP477, Figure 6A); and the three most enriched
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cellular components from the 2018 Gene Ontology project were all mitochondrial
components (Figure 6B).

To test this prediction of altered mitochondrial function in tissues distant from the
primary tumor in vivo, we generated 6 female BC-PDOX mice and isolated live
mitochondria from their skeletal muscle at euthanasia for quantification of ATP content.
We found a significant reduction in ATP content within both of the two major skeletal
muscle mitochondrial subpopulations, the interfibrillar mitochondria (IFM) and
subsarcolemmal mitochondria (SSM), relative to female control animals (Figure 6C).
We additionally quantified ATP content in snap-frozen muscle biopsies from a large
group of women with BC and control patients. Consistent with our in silico predictions
and murine studies, bulk muscle from BC patients was quantified as having significantly
less ATP per gram of protein than control muscle, though the large degree of variability
in absolute quantifications should be noted (Figure 6D). In vitro assays were conducted
to determine whether mitochondrial dysfunction in muscle is a direct response to BCsecreted factors or an indirect response mediated by other tissues. In support of a direct
response, conditioned media from the luminal EO771 BC cell line and the HER2/neu
overexpressing NF639 line significantly repressed aerobic ATP production in
differentiated C2C12 myotubes, whereas media conditioned by either the normal
mammary epithelial cell line EpH4-EV or C2C12 myoblasts did not (Figure 6E). To
validate the role of the PPAR signaling proteins in mediating the systemic response to
BC-secreted factors, conditioned media was isolated from EO771 and NF639 cells and
applied to HEK293 cells stably expressing a PPAR-responsive promoter driving GFP
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expression. Media conditioned by both BC cell lines significantly repressed GFP
intensity relative to reporter cell conditioned media, while media conditioned by a normal
mammary epithelial cell line did not alter GFP signal relative to control (Figure 6F).
These data indicate that BC cells secrete a substance that is capable of directly
influencing metabolic function in skeletal muscle, which may be related to a repression
of PPAR-mediated transcriptional activity.
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DISCUSSION
BC-induced muscle dysfunction is a common problem of unclear etiology with few
therapeutic options. Here we sought to identify possible mechanisms of fatigue that are
generalizable across BC subtypes and are independent of treatment status by
assessing statistical relationships between patients’ clinical characteristics and overall
skeletal muscle molecular composition.
In support of our laboratory’s previous publications 14,15, we found that women with
three molecular subtypes of BC, those being ERPR, TN, and TP BC, exhibit overall
similarity in muscular gene expression. Remarkably, patients with tumors
overexpressing HER2/neu in the absence of ER and PR expression exhibited a
markedly different muscular gene expression profile. However, gene expression data
from all subtypes pointed to similar pathway-level dysregulation, indicating that the
mechanisms leading to muscle fatigue in BC patients may indeed be generalizable
across subtypes, although we acknowledge this conclusion is based on a limited
sample size across individual BC subtypes. In assessing the commonalities across
patients, we observed significant dysregulation of metabolic pathways in all groups of
BC patients, and proteomic analysis of patients with HER2/neu-overexpressing tumors
showed decreased abundance of nearly all proteins involved in the mitochondrial
electron transport chain. Because mitochondrial density in skeletal muscle has been
shown to correlate with abundance of ETC complex proteins and skeletal muscle
oxidative capacity 18, it is likely that BC patients also have decreased mitochondrial
densityl in their skeletal muscle as well as decreased oxidative capacity. We propose
then that BC-secreted factors induce muscle dysfunction by abrogating oxidative
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capacity via alteration of mitochondrial biogenesis, mitophagy, or fission/fusion
dynamics. Both in vitro and in vivo assays confirm that factors from BC cells alter
skeletal muscle ATP content and/or aerobic ATP production, perhaps via dysregulation
of the PPAR-signaling pathway.
Our laboratory’s interest in the PPAR family of proteins arose from our previous RNAseq analysis of muscle from BC patients and PDOX-bearing mice, which our group
found to recapitulate the clinical phenotype of increased muscle fatigue without muscle
atrophy or bodyweight loss 15. These proteins have demonstrated roles in whole-body
energy regulation, are critical regulators of mitochondrial function in multiple tissues,
and are targets of multiple
FDA-approved agents in the treatment of type 2 diabetes and hyperlipidemia. Among
the three PPAR isoforms, we identified PPARG as a key regulator in BC-induced
muscle dysfunction observed in PDOX mice 15. PPARG is a ligand-activated nuclear
receptor that, upon activation by a variety of endogenous and synthetic lipids, forms
complexes with retinoid X receptor (RXR) and cofactors such as the peroxisome
proliferator-activated receptor-γ coactivator 1α (PGC1α), and stimulates transcription of
downstream genes. This relationship with PGC1α is particularly relevant, as PGC1α is
known to be a master regulator of mitochondrial biogenesis in several tissues, including
skeletal muscle 19. PGC1α also participates in the regulation of other metabolic
processes, including gluconeogenesis, muscle fiber-type specification, and control of
antioxidant expression 20-22. Therefore, the interaction between PPARG and PGC1α
clearly has the potential to impact muscle function through mitochondrial mechanisms.
In addition to the potential development of muscle-intrinsic mitochondrial dysfunction, a
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systemic consequence of dysregulated PPARG is the development of insulin resistance
(IR) 23, which is commonly associated with type 2 diabetes, obesity, and metabolic
syndrome, and appears to have a bidirectional relationship with BC, with individuals with
IR at greater risk of BC and BC survivors at an increased risk of IR 24,25. We propose
that the development of mitochondrial dysfunction and IR, secondary to muscular
PPARG downregulation by BC, creates an environment that facilitates the development
of muscle fatigue through several mechanisms, including decreased mitochondrial ATP
production as well as dysregulated glucose and lipid metabolism. Pharmacological
restoration of PPARG function results in the induction of a number of genes involved in
insulin signaling, as well as glucose and lipid metabolism, and PPAR agonist drugs
including the thiazolidinediones have shown a remarkable ability to restore insulin
sensitivity in insulin-resistant conditions. Because our predictions have implicated many
related metabolic pathways, we hypothesize that the development of BC induced
muscle fatigue constitutes a pathology similar to type 2 diabetes/metabolic syndrome. If
repression of PPAR signaling is indeed central to BC-induced muscle dysfunction, the
numerous FDA-approved PPAR-agonists could address this unmet need in clinical
oncology.
A particularly surprising result in the present study was that no clinical data aside from
BC molecular subtype exhibited significant correlation with skeletal muscle gene
expression, including TNM staging and history of chemotherapy, radiation, or
immunotherapy. Additionally, patients in the HER2 group consistently exhibited a
decreased abundance of mitochondrial proteins in their muscle tissue, and importantly,
we observed these responses consistently across all five biopsies from this patient
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group despite significant differences in anti-cancer treatment history. At the date of
biopsy collection, one patient was entirely treatment naïve, one patient had completed
chemotherapy for BC 10 years prior, and the remaining 3 patients received different
multi-agent neoadjuvant chemotherapy in the months prior to surgery. Therefore, we
propose that changes in skeletal muscle physiology seen in BC are due to tumorderived factors rather than side effects of therapies or other patient-specific factors. This
hypothesis is supported by our in vitro conditioned media experiments where tumorderived factors directly repressed mitochondrial respiratory capacity in differentiated
muscle cells. Additionally, neither weight loss nor body composition were predictive of
skeletal muscle gene expression, suggesting that gene expression changes observed in
BC patients are unrelated to muscle atrophy or cachexia and may instead be reflective
of muscle dysfunction. Therefore, the molecular alterations we highlight suggest that
skeletal muscle is responding at the early stages of breast tumor growth, at a time when
patients would be considered “pre-cachectic”, based on Fearon’s cachexia continuum 1.
Clinicians should be aware that patients with BC may not have dramatic changes in
body weight and/or muscle mass during tumor growth or tumor-directed therapies.
However, this does not necessarily imply that muscle dysfunction, in the form of
persistent fatigue, is not adversely affecting patients’ quality of life.
Because albumin is often used by physicians as a measure of patients’ nutritional
status and mortality risk 26-29, we assessed serum albumin in our patient cohort and
assessed its relationship to skeletal muscle gene expression and weight change. In our
analysis, serum albumin was not found to be predictive of weight change, and in a
larger sample was found to be only weakly predictive of cachexia risk. Yet, it was
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unexpectedly predictive of skeletal muscle gene expression. This indicates that serum
albumin may be a useful biomarker of muscle function during pre-cachexia, a possibility
supported by previous literature connecting serum albumin with muscle strength 30 and
insulin resistance 31 in other clinical contexts. Prospective studies directly addressing
the relationship between skeletal muscle function, gene expression, and serum albumin
would be required to validate the clinical utility of serum albumin in identifying those at
risk of cancer-induced muscle dysfunction.
In line with our previous publications 14,15, we report that transcriptional responses to
the ERPR, TP and TN subtypes of BC are similar in terms of skeletal muscle gene
expression, while muscle biopsies from patients with tumors overexpressing HER2/neu
in the absence of ER and PR exhibit an unusual degree of uniqueness in terms of gene
expression. We identified a strong signal for BC-induced mitochondrial dysfunction in
BC patients, PDOX-bearing animals, and in in vitro assays, and proteomic analysis
showed decreased protein abundance of nearly all components of the mitochondrial
electron transport chain in muscle biopsies from patients with HER2/neu-overexpressing
tumors relative to control. Further, we found no relationship between various BC-related
treatments (surgery, chemotherapy, radiotherapy) and changes in skeletal muscle gene
expression. However, serum albumin was predictive of skeletal muscle gene expression
without being predictive of weight loss, suggesting that serum albumin may be a useful
indicator of BC-induced skeletal muscle dysfunction. Overall, these data indicate that all
BC is associated with dysfunction in mitochondrial respiration in skeletal muscle
independent of molecular subtype, and this effect appears to be independent of anticancer treatments. These findings call for prospective studies assessing interventions to
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support skeletal muscle function in the presence of BC-induced mitochondrial
dysfunction.
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METHODS
Patient information. Conduct of research involving human patients at West Virginia
University is guided by the principles set forth in the Ethical Principles and Guidelines
for the Protection of Human Subjects of Research (Belmont Report) and is performed in
accordance with the Department of Health and Human Services policy and regulations.
A total of 71 female surgical patients provided informed consent for inclusion in this
study (control n=20; BC n=51). Informed written consent was obtained from each
subject or each subject’s guardian. Individuals could be included in this study if they 1)
were deemed to have operable disease or were undergoing a diagnostic biopsy, 2) had
been diagnosed with, or were suspected to have, invasive adenocarcinoma of the
breast, 3) were over 21 years old, and 4) provided informed consent. Women with BC
provided muscle biopsies from the pectoralis major muscle intraoperatively at the time
of mastectomy, and control patients provided pectoralis major muscle samples
intraoperatively during other breast surgeries. Women with BC were classified into four
molecular subtypes based on immunohistochemical staining of their primary tumors:
ERPR (n=20), HER2 (n=9), TN (n=11), or TP (n=11).
Information on BMI at multiple time points was collected in 12 control and 50 BC
patients. The mean number of days a consented patient was followed was 170 +/- 214
(control median=170, ERPR median=36, HER2 median=146, TP median=140, TN
median=180). Detailed body composition analyses were acquired in 8 control and 35
BC patients using a bioelectrical impedance scale (Tanita: model SC-240). Serum
albumin levels were acquired in 3 control and 49 BC patients (ERPR n=18; HER2 n=9;
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TP n=11; TN n=10). For RNA-Seq analyses, biopsies were used from 10 control and 33
BC patients (ERPR n=10; HER2 n=5; TP n=9; TN n=9).
In a separate analysis of de-identified electronic medical records (EMRs) from female
BC patients, body mass and standing height data were acquired for 5,201 individuals for
calculation of BMI. Within this population, final analyses were completed in 3,001
patients having at least two measurements for weight in addition to at least one record
for serum albumin.
RNA-Sequencing. Pectoralis major muscle biopsies were acquired intraoperatively and
stored in RNA stabilization reagent (Invitrogen, Thermo Fisher, San Jose, CA) overnight
at 4oC and then at 80oC until processing. RNA was isolated, assessed for quality, and
utilized to construct libraries for RNA-Seq as previously reported 15. Completed libraries
were sequenced on one lane of the HiSeq 1500 with PE50 bp reads, with approximately
15 million reads per sample. Subsequently, Salmon was used for transcript-level
abundance estimation, with both gcBias and seqBias set, and libType A 32, using the
GRCh38 genome assembly. Between 5-10% of reads in each sample were unable to
be mapped and were excluded from analyses reported here. Transcript-level
abundance estimates were summarized to the gene-level using tximport 33. The
resulting counts matrix was scaled to library size using edgeR 34 and filtered to remove
genes without a counts-per-million (CPM) value > 1 in 3 or more samples. Logtransformed CPM values for the 10,000 genes with highest variance were used as input
for hierarchical clutering using gplots 35. CPM values of all genes with CPM > 1 in at
least 3 samples were scaled and log-transformed prior to distance matrix computation,
which was then input for classical multidimensional scaling with k=3 and visualized in 3-
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dimensions using car 36. This 3-dimensional distance matrix (3D-MDS) was then utilized
as 3 response variables representing gene expression in the multivariate regression
analysis to assess statistical relationships between clinical parameters and overall gene
expression. Differential gene expression analysis was conducted using DESeq2 37. Both
the multivariate regression analysis and differential expression analysis are further
described below, within “RNA-Seq and clinical correlates” in the Statistical Analyses
section. Power was determined post hoc to be 88% using RnaSeqSampleSize 568 with
1000 repetitions, f=0.1, and rho=2.
Proteomics. Sample Preparation: Pectoralis major muscle biopsies from n=5
female patients with HER2/neu-overexpressing BC and n=5 control breast
surgical patients were acquired intraoperatively and stored in RNA-later at 80oC until processing
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. Muscle biopsy samples weighing approximately 50mg

were sent on dry ice to the Mass Spectrometry and Proteomics Resource
Laboratory at Harvard University and processed according to established
protocols 40,41. Briefly, biopsies were lysed in Covaris® microTUBE- 15 (Woburn,
MA) microtubes with Covaris® TPP buffer, using the Covaris S220 Focusedultrasonicator instrument with 125W power over 180s with 10% max peak
power. Samples were then chloroform/methanol precipitated, filtered, reduced,
alkylated, and finally digested overnight at 38oC in a solution containing
triethylammonium bicarbonate and Promega® Sequencing Grade Trypsin.
Digested peptides were then incubated with tandem mass tag, using different
tags for each sample.
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LC-MS/MS: The 10 samples were pooled in equal amounts and fractionated
into 10 fractions. LC-MS/MS was performed on an Orbitrap Lumos (Thermo
Fisher) equipped with EASYLC1000 (Thermo Fisher). Peptides were separated
onto a 100 µm inner diameter microcapillary column packed first with C18
Reprosil resin (5 µm, 100 Å, Dr. Maisch GmbH, Germany) followed by
analytical column of Reprosil resin (1.8 µm, 200 Å, Dr. Maisch GmbH,
Germany). Separation was achieved through applying a gradient from 5– 27%
acetonitrile in 0.1% formic acid over 90 min at 200 nl·min−1. Electrospray
ionization was enabled through applying a voltage of 1.8 kV using a homemade
electrode junction at the end of the microcapillary column and sprayed from
fused silica pico tips (New Objective, MA). The LTQ Orbitrap Lumos was
operated in data-dependent mode for the mass spectrometry methods. The
mass spectrometry survey scan was performed in the Orbitrap in the range of
395 –1,800 m/z at a resolution of 6 × 104, followed by the selection of the
twenty most intense ions (TOP20) for collision induced dissociation (CID) in the
Ion trap using a precursor isolation width window of 2 m/z, AGC setting of
10,000, and a maximum ion accumulation of 200 ms. Singly charged ion
species were not subjected to CID fragmentation. Normalized collision energy
was set to 35 V and an activation time of 10 ms. Ions in a 10 ppm m/z window
around ions selected for MS2 were excluded from further selection for
fragmentation for 60 s. The same TOP20 ions were subjected to higher-energy
collisional dissociation (HCD) MS2 event in Orbitrap part of the instrument. The
fragment ion isolation width was set to 0.7 m/z, AGC was set to 50,000, the
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maximum ion time was 200 ms, normalized collision energy was set to 27V and
an activation time of 1 ms for each HCD MS2 scan.
Mass spectrometry analysis: Raw data were submitted for analysis in Proteome
Discoverer 2.2 (Thermo Scientific). Assignment of MS/MS spectra was performed using
the Sequest HT algorithm by searching the data against a protein sequence database
including all entries from Uniprot_Human2016_SPonly database as well as other known
contaminants such as human keratins and common lab contaminants. Sequest HT
searches were performed using a 20 ppm precursor ion tolerance and requiring each
peptides N-/C termini to adhere with trypsin protease specificity, while allowing up to two
missed cleavages. 6-plex TMT tags on peptide N termini and lysine residues
(+229.162932 Da) were set as static modifications while methionine oxidation
(+15.99492 Da) was set as a variable modification. A MS2 spectra assignment false
discovery rate (FDR) of 1% on both protein and peptide level was achieved by applying
the target-decoy database search. Filtering was performed using a Percolator 42 (64bit
version). For quantification, a 0.02 m/z window centered on the theoretical m/z value of
each the six reporter ions and the intensity of the signal closest to the theoretical m/z
value was recorded. Reporter ion intensities were exported using Proteome Discoverer
2.2.
Western blotting analysis. Pectoralis major muscle biopsies from n=13 female
patients with BC and n=10 control breast surgical patients were snap-frozen and stored
at -80oC until processing. Biopsies from n=7 female patients with BC and n=7 control
breast surgical patients were selected from this pool using stratified random sampling
by patient group (i.e. BC or CON) without regard to patient molecular subtype. Protein
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homogenates were made using a 5 mL Wheaton tissue grinder (DWK Life Sciences
Inc., Millville, NJ, USA) in a solution of 20 mM Tris HCl (pH = 7.4), 150 mM NaF, 1 mM
EDTA, 1% Triton X-100, and 10% glycerol. Homogenates were cleared via brief
centrifugation, and protein concentration was quantified using DC™ Protein Assay (BioRad, California, USA) according to manufacturer’s protocol. 12 µg of total protein was
loaded per well and resolved in NuPAGE Novex 4-12% Bis-Tris Gels (ThermoFisher
Scientific). Proteins were transferred to nitrocellulose membrane, Ponceau stained to
assess loading, destained, blocked in 1X tris-buffered saline (TBS), 0.1% Tween20, 5%
milk, then incubated with primary antibody overnight at 4°C. Membranes were then
washed prior to application of appropriate secondary antibody (ThermoFisher
Scientific), and again prior to application of Pierce ECL Western Blotting Substrate
(ThermoFisher Scientific). Relative band intensity was quantified using the GE
Amersham Imager 600 (GE Healthcare Life Sciences, Marlborough, MA, USA). GAPDH
and Ponceau staining are presented as loading controls but were not used to normalize
densitometry data. Primary antibodies included CKMT2 (ThermoFisher Scientific, #PA528591), COX7A1 (ThermoFisher Scientific, #PA5-67696), and GAPDH (Cell Signaling
Technology, Massachusetts, USA, #2118S).

BC patient muscle ATP quantification. Pectoralis major muscle biopsies from n=13
female patients with BC and n=10 control breast surgical patients were snap-frozen and
stored at -80oC until processing as described under “Western blotting analysis.” All
available snap-frozen muscle biopsies were included in analysis of ATP content. ATP
content was quantified using the ENLITEN® ATP Assay System Bioluminescence
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Detection Kit (Promega, Wisconsin, USA) according to manufacturer’s protocol, using
the manufacturer’s recommended standard curve for calculation of absolute ATP
content from luminescence intensity and The FlexStation® 3 Multi-Mode Microplate
Reader (Molecular Devices®, California, USA). ATP content was normalized to protein
concentration, quantified using the DC™ Protein Assay (Bio-Rad, California, USA).

BC-PDOX skeletal muscle mitochondria metabolic analysis. Animal experiments
were approved by the WVU Institutional Animal Care and Use Committee. BC-PDOX
mice were created by implanting human BC tumor fragments into the mammary fat pad
of female NOD.CG-Prkdscid Il2rgtm1 Wjl/SzJ/ 0557 (NSG) mice (n=6), as described
previously 15. PDOX-bearing animals were euthanized approximately 30 days after
reaching a tumor volume of 200 mm3. Control female NSG mice of similar age (n=4)
were euthanized at the same time as tumor-bearing animals and tissues were
processed identically in both groups. Immediately after death, both quadriceps muscles
from each mouse were quickly removed and interfibrillar (IFM) and subsarcolemmal
(SSM) mitochondria were isolated separately according to previously described
methods 43-46, combining the two muscles to obtain sufficient tissue for downstream
applications. Mitochondrial isolates were stored at -80oC until analysis. ATP content was
quantified in each mitochondrial subpopulation using the ENLITEN® ATP Assay System
Bioluminescence Detection Kit (Promega) according to manufacturer’s protocol with
minor modifications, as follows. Mitochondrial isolates were lysed in 1% trichloroacetic
acid for 5 minutes then diluted 1:10 in 0.1 mol·L-1 tris base (pH = 7.8). The resulting
samples were loaded into a black-walled microplate, in duplicate, and mixed 1:1 with
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luciferase/luciferin reagent. Luminescence intensity was immediately read using the
FlexStation® 3 Multi-Mode Microplate Reader (Molecular Devices®, California, USA).
Luminescence intensity values were blank-corrected and normalized to account for
differing protein concentrations, which were quantified using the DC™ Protein Assay
(Bio-Rad, California, USA).
Cell culture. All cell lines were obtained from ATCC (Virginia, USA) with the exception
of EO771s. Cells were cultured in Gibco DMEM (Thermo Fisher, Massachusetts, USA)
supplemented with 10% heat inactivated fetal bovine serum (Atlanta Biologicals,
Georgia, USA) and Gibco penicillin/streptomycin (Thermo Fisher) at 37oC with 6% CO2.
Cell lines utilized include EpH4-EV (immortalized normal murine mammary epithelium),
EO771 (murine luminal BC), NF639 (murine HER2/neu-overexpressing BC), HEK293
(human embryonic kidney), and C2C12 (murine myoblasts).

In vitro conditioned media (CM) metabolic analysis. C2C12 cells were plated into Agilent
Seahorse XF24 (Agilent Technologies, California, USA) plates and differentiated by
confluence for 3 days. Meanwhile, EpH4-EV, EO771, NF639, and C2C12 cells were
plated at approximately 15% confluence in separate 10cm dishes for 72 hours. The 72hour CM was then removed from all cell lines, centrifuged at 1,500 RPM for 10 minutes,
and then the supernatants were collected, diluted 1:3 in fresh growth media, and
applied to the differentiated C2C12 cells in Seahorse assay plates for 48 hours (n=10
wells per treatment condition) prior to conducting the Agilent Seahorse XF Cell Mito
Stress Test protocol according to manufacturer’s instructions.
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In vitro CM PPAR-reporter assays. HEK293 cells were transfected with PPRE-H2beGFP 47(Addgene #84393) using Invitrogen Lipofectamine 3000 (Thermo Fisher),
selected with 500 ng·uL-1 Gibco geneticin (Thermo Fisher) for 20 days, and flow-sorted
to select the cells expressing GFP. The resulting HEK293-PPRE-H2b-eGFP cell line
was plated at approximately 15% confluence in a 24-well plate. The following day, cells
were imaged using the BioTek Cytation 5 Cell Imaging Multi-Mode Reader (Agilent
Technologies) to collect baseline GFP intensity, and 72-hour conditioned media from
HEK293, EpH4-EV, EO771, and NF639 cell lines was applied to the 24-well plate, using
individual wells as biological replicates (n=6 wells per treatment condition). Cells were
then incubated in the conditioned media under normal culture conditions for 24 hours, at
which point GFP intensity was measured using identical imaging settings as the
baseline collection. Mean cellular GFP intensity per well was calculated using Gen5
Microplate Reader and Imager Software (Agilent Technologies) after background
flattening and thresholding, which were set consistently across all images.
Statistical Analyses.
Clinical information: Patients’ trends of weight change over time were calculated for
each individual patient by fitting a simple linear regression line to their weight at each
date in the EMR, normalized such that each patient’s first weight record equaled 100,
resulting in a slope representing their approximate percentage of body weight change
per day. 19 patients were identified as outliers in terms of daily weight change. 13 of
these patients were excluded due to having a limited observation period (< 15 days).
Each patient’s first albumin measurement was then obtained and the rate of daily weight
change was regressed on the patients’ first albumin measurements. Pearson’s
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correlation coefficients and p-values were calculated and plotted using ggpubr 48 in R
v3.6.1 49.
Logistic regression analysis was utilized to determine whether serum albumin
was predictive for a rate of weight change consistent with cachexia (i.e. < -0.027% per
day to reach 5% weight loss in 6 months 1,2). Omnibus model fit was assessed by Chisquare test and effect size was calculated using Nagelkerke’s pseudo-R2. The receiver
operating characteristic curve (ROC) test was conducted, with preferred sensitivity and
specificity > 0.7. No point on the ROC satisfied these conditions. The fitted logistic
regression model was used to predict whether each patient would exhibit a rate of
weight loss consistent with cachexia, and these predictions were compared to the actual
data to create a confusion matrix for determination of sensitivity, specificity, and positive
predictive value.
RNA-Seq and clinical correlates: A multivariate regression model was used to assess
clinical data against the 3D-MDS representing overall skeletal muscle gene expression,
obtained as described above within “RNA-Sequencing.” Each clinical variable available
was regressed on the 3D-MDS and model fit was assessed via MANOVA and Pillai’s
trace. Forward selection was then applied to combine the variables with smallest pvalues for Pillai’s trace into a final model, with final selection considerations including
statistical significance for MANCOVA using Pillai’s trace and Wilks’ lambda, maximizing
Pillai’s trace test statistic, and minimizing Wilks’ lambda test statistic.
Differential gene expression analysis was conducted using DESeq2 35. Input data
consisted of transcript-level abundance estimates from Salmon summarized to the gene
level using tximport 31. Two differential expression analyses were run: one comparing
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the group of BC patients to control patients, and another comparing the BC patients by
subtype to control patients, with the null hypothesis rejected at FDR < 0.10. Because
molecular subtype was the only variable that yielded statistical significance for
predicting gene expression in the multivariate regression model described above, no
clinical characteristics were assessed in the differential expression analysis.
Proteomics: Differential protein expression analysis was conducted using DEP 50.
Protein expression values were first filtered to remove known contaminants and proteins
with missing expression values in more than 1 sample per group, then normalized, and
then background-corrected using variance stabilizing transformation. Remaining
missing values were imputed using k-nearest neighbor, after determining that the small
number of missing values were likely missing at random. Differential expression
analysis using linear models and empirical Bayes statistics was then conducted on the
imputed dataset, with the null hypothesis rejected at FDR < 0.05.
Enrichment analyses: Input data for GSEA included normalized gene expression counts
for each patient for all genes with at least 1 CPM in at least 3 patients, with ranking
conducted within GSEA using “Signal-to-noise” based ranking. Reference gene sets
included all KEGG v7 pathways accessed from Molecular Signature Database 51 with at
least 15 genes in the pathway in our gene set for RNA-seq results and at least 10 genes
in the pathway in our gene set for proteomics. Only pathways identified as enriched at
q-value < 0.05 are reported here. Input data for Enrichr 52-53 analyses included only the
list of significantly differentially expressed genes and proteins. In Enrichr, all databases
were queried, with particular interest in ENCODE and ChEA Consensus TFs for
transcription factor target enrichment, WikiPathways 2019 Human for pathway analysis,
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and 2018 databases from the Gene Ontology project for cellular component, biological
process, and molecular function enrichment analyses. Data presented in this article
reflect analyses conducted in Enrichr between May 15th and June 15th of 2019 and in
GSEA between March 1st and March 30th 2020. Ingenuity Pathway Analysis (Qiagen,
Germany) was utilized for visualization of affected pathways.

In vitro and in vivo validation assays: ATP content in each mitochondrial subpopulation
in the PDOX muscle were compared to control using the Wilcoxon rank sum test. The
null hypothesis was rejected at p < 0.05. In the conditioned media metabolic
experiments, one-way ANOVA was used to compare the rate of oxygen consumed in
ATP production as a percentage of basal oxygen consumption between the four
conditioned media treatment groups followed by two-tailed Student’s t-tests with HolmBonferroni correction comparing each treatment group to CONMuscle. The null
hypothesis was rejected at p < 0.05. This experiment was conducted as reported twice
with similar results, and results from the first analysis are reported. In the PPARresponsive reporter assays, mean GFP intensities in each well were normalized to
account for differences in baseline GFP expression between wells. Normalized GFP
intensities at 24 hours were compared to normalized baseline measurements using a
paired samples two-tailed t-test by treatment group with Holm-Bonferroni correction for
multiple comparisons. The null hypothesis was rejected at p < 0.05. This experiment
was conducted as reported twice with similar results, with results from the first analysis
reported. This analysis includes n=5 for NF639-treated cells due to a technical problem
during baseline image capture that resulted in the loss of one image.
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Chi-Square analyses: First, the actual number of unique and shared DEGs and
dysregulated pathways were counted for each subtype. For example:
HER2-unique = genes differentially expressed only in HER2 patients
HER2-2-Group = HER2 ∩ ERPR

+ HER2 ∩ TP

+ HER2 ∩ TN;

HER2-3-Group = HER2 ∩ ERPR ∩ TP + HER2 ∩ ERPR ∩ TN + HER2 ∩ TN ∩
TP. Then, expected numbers of DEGs and dysregulated pathways were calculated
under the null hypothesis that DEGs and dysregulated pathways are independent of BC
subtype. Chi-square statistics were calculated using the difference between observed
and expected numbers of DEGs and dysregulated pathways. On 6 degrees of freedom,
the Chi-square critical value is 12.592 for statistical significance at α = 0.05. Bar plots
represent the log-fold change in number of DEGs or dysregulated pathways compared
to expected values, by category, and actual Chi-square statistics for each category are
also provided.
Box-and-whisker plots: The width of the box represents the interquartile range (IQR)
and whiskers extend to the single most extreme measurement in both directions, unless
the most extreme measurement is considered an outlier, in which case the most
extreme value is represented a dot without a connected whisker. Median values are
represented by the horizontal line through each boxplot. Outliers in this context are
defined as values more extreme than 1.5 x IQR.
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DATA AVAILABILITY
Gene expression counts for RNA-seq and individual protein abundance estimates for
proteomic data in human muscle biopsies have been provided for all patients
(Supplemental Tables 1 and 2). At the time that we formulated our IRB Consent Form
and started collecting muscle biopsies (December 2015), we did not have the foresight
that the transcriptomic and proteomic data would need to be made available publicly in
a more raw form. Our IRB Consent Form does not contain language pertaining to this,
and therefore, the patients did not give consent to having their genetic information made
publicly available. Reconsenting the patients in our study is logistically difficult, if not
impossible, since some of our original patients may have completed treatment and are
not visiting the Cancer Institute currently, or unfortunately may not have survived to this
date. We acknowledge that this was an unfortunate error on our part.
Article Preprint:
This manuscript was previously published as a preprint at BioRxiv:
http://biorxiv.org/cgi/content/short/810952v1. Revisions have been made in response to
peer review.
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FIGURES AND FIGURE LEGENDS
Figure 1: Skeletal Muscle Gene Expression Profiles.

Unsupervised hierarchical clustering of individual patients on normalized, logtransformed RNA-seq gene expression data of the 10,000 most variable genes across
all patients (A, top) and first two principal components calculated using filtered,
normalized, log-transformed RNA-seq gene expression data with samples colored
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according to BC molecular subtype with group geometric means denoted with larger
symbols (A, bottom). MDS dissimilarity matrix of overall gene expression data
represented in 3 dimensions, with each dot representing an individual patient.
Regression planes are color-coded based on molecular subtype (B), binary disease
status (C), or the null model (D).
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Figure 2: Serum Albumin and Weight Loss.

Linear regression analysis of trends in weight change predicted by serum albumin in
patients with BC who provided muscle biopsies and at least one serum albumin
measurement. Grey dots represent individual patients; grey shading represents 95%
confidence interval of the black regression line, with marginal kernel density plots
provided for both variables (A, n=51). Linear regression analysis of trends in weight
change predicted by serum albumin in a retrospective chart review of patients with BC.
Grey dots represent individual patients; grey shading represents 95% confidence
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interval of the black regression line, with marginal kernel density plots provided for both
variables (B, n=3,001). Histogram representing individualized rate of weight change in a
retrospective chart review of patients with BC, with patients grouped by serum albumin
level (C, nlow=442, nnormal=2,557).
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Figure 3: Differential Gene Expression Analysis by Subtype.

Venn diagram representing DEGs in muscle in each molecular subtype (A) and
corresponding area-representative Chow-Ruskey diagram (B). Chi-square analysis of
the number of DEGs uniquely differentially expressed in each subtype, the number of
DEGs involved in 2- and 3-way overlaps among subtypes, showing the log-fold change
between observed and expected numbers in each category. The Chi-square critical
value of 12.592 (6 degrees of freedom) is denoted on the Chi-Square y-axis by a gray
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horizontal line. A Chi-square value larger than 12.592 is statistically significant at α =
0.05. (C).
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Figure 4: Dysregulated Pathway Analysis by Subtype.
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Venn diagram representing significantly dysregulated KEGG pathways in muscle in
each molecular subtype (A) and corresponding area-representative Chow-Ruskey
diagram (B). Chi-square analysis of the number of pathways uniquely dysregulated in
each subtype and those involved in 2- and 3-way overlaps between subtypes, showing
the log-fold change between observed and expected numbers in each category. The
Chi-square critical value of 12.592 (6 degrees of freedom) is denoted on the Chi-square
y-axis by a gray horizontal line. A Chi-square value larger than 12.592 is statistically
significant at α = 0.05. (C). Heatmap of normalized enrichment scores from GSEA for
the nineteen commonly dysregulated pathways across all subtypes, with the four
columns of the heatmap representing the four molecular subtypes. Lower enrichment
scores in blue indicate genes within that set are generally downregulated in the BC
group, and higher enrichment scores in red indicate general upregulation in BC group
relative to control (D).
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Figure 5: HER2 Patient Proteomics.
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Stacked bar chart representing the number of unique proteins detected by the number
of samples (A, n=10 biopsies, n=1,555 unique proteins). Differential expression analysis
of detected proteins, represented as a volcano plot with significantly differentially
expressed proteins (DEPs) identified in black (B). Heatmap of DEPs, with the ten
columns representing the ten samples assayed (C). Enrichment analysis on the DEPs,
querying Gene Ontology 2018 Cellular Components via Enrichr; top three results as
ranked by Enrichment Score (D). Ingenuity Pathway Analysis representation of the
mitochondrial electron transport chain, with proteins detected at lower abundance in the
BC patient group notated in green (E). Western blot validation of two DEPs, using an
independent cohort of BC and CON patients with Ponceau staining and GAPDH
presented as loading controls (F).
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Figure 6: Subtype-Independent DEG Analysis and Experimental Validation.
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Enrichment analysis of DEGs, querying WikiPathways 2019 Human database. Top hits
ranked by Enrichment Score (A). Enrichment analysis of DEGs, querying Gene
Ontology 2018. Top hits ranked by Enrichment Score (B). Enrichment Score and pvalue reported as provided by Enrichr. A –log(p) > 1.3 corresponds to p < 0.05 (A, B).
ATP content in quadriceps muscle of control (n=4) and PDOX-bearing (n=6) mice as
assessed by chemiluminescence in two mitochondrial subpopulations. ATP content in
the PDOX mitochondria was compared to control using the Wilcoxon rank sum test (C).
ATP content in pectoralis major muscle of control (n=10) and BC patients (n=13) as
assessed by chemiluminescence using a standard curve for absolute quantification and
normalized to protein content. ATP content in the BC group was compared to control
using the Wilcoxon rank sum test (D). Aerobic ATP production as a percentage of basal
oxygen consumption rate (OCR) in differentiated C2C12 myotubes treated for 48 hours
with media conditioned by C2C12 (CON-Muscle), EpH4-EV (CON-Mammary), EO771
(BC), or NF639 (BC) cells (n=10 per group). Overall significance determined by oneway ANOVA followed by two-tailed Student’s t-tests with Holm-Bonferroni correction
comparing each treatment group to CON-Muscle (E). Normalized GFP intensity in
HEK293-PPRE-H2b-eGFP reporter cells at baseline and after treatment with
conditioned media for 24 hours (n=6 for HEK293, EpH4-EV, and EO771; n=5 for
NF639). Normalized GFP intensity values at 24 hours were compared to baseline
measurements using paired samples two-tailed t-tests with Holm-Bonferroni correction
of p-values (p. adj) (F).
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Supplemental Figure 1.

Scaled, log-transformed protein expression correlated with scaled, log-transformed RNA
expression in a gene-wise fashion, presented for 8/8 patients with both RNAseq and
proteomic analyses.
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Supplemental Figure 2.

GSEA using proteomic data from muscle biopsies from n=5 women with HER2overexpressing tumors and n=5 control patients.
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TABLES

Table 1: Patient Characteristics
Patient Group BMI (kg.m-2)

Control 32.7 ± 7.8
All Cancer 29.9 ± 7.4

BMI Change

Body Fat

Lean Body

Number of

(%)

(%)

Mass (kg)

Days in Record

-0.16 ± 2.9

37.7 ± 7.5

45.9 ± 6.3

220.1 ± 135.1

-0.32 ± 5.10

35.5 ± 3.9

46.4 ± 5.6

156.0 ± 242.0

ERPR 28.6 ± 4.5

-0.54 ± 2.9

84.20 ± 161.1

HER2 31.1 ± 7.8

1.12 ± 5.9

159.9 ± 131.9

TN 29.6 ± 6.5

0.07 ± 6.3

313.5 ± 426.6

TP 31.6 ± 11.6

-1.47 ± 6.5

125.8 ± 94.99

t-Test, two-tailed p p = 0.18
(Df, t) (69, 1.36)
ANOVA p = 0.70
(Dfbetween, Dfwithin, F) (3, 47, 0.47)

p = 0.90

p = 0.24

p = 0.82

p = 0.27

(69, 0.13)

(41, 1.19)

(41, 0.22)

(69, 1.12)

p = 0.72

p = 0.08 o

(3, 47, 0.45)

(3, 47, 2.38)

All values are presented as mean ± standard deviation; Df- degrees of freedom; o p < 0.10
t-Test: control vs. all cancer
ANOVA: among patient groups
BMI - body mass index; ER – estrogen receptor; PR – progesterone receptor
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Table 2: Possible clinical predictors of muscular gene expression
Variable

Group

Variable Type

Pillai’s

Num

Den

p

(Levels or Range)

Trace

Df

Df

Factor

0.51

12

111

0.04 *

(Control, ERPR, HER2, TN, TP)
Serum Albumin

Numeric

0.20

3

29

0.08 o

N Staging

Factor (N0, N1, N1a, N2, N3)

0.52

12

84

0.15

# of Chemotherapy Txs

Numeric (0-2)

0.10

3

38

0.25

# of Radiation Txs

Numeric (0-1)

0.10

3

38

0.26

T Staging

Factor (T1, T1a, T2, T2A, T3, T4)

0.51

15

81

0.37

# of Hormonal Txs

Numeric (0-1)

0.07

3

38

0.43

LBM %

Numeric

0.12

3

19

0.45

BMI

Numeric

0.05

3

38

0.56

Ave. Daily BMI Change Numeric

0.03

3

37

0.78

0.01

3

29

0.95

M Staging

Factor (M0, MX)

Num- numerator; Den- denominator; Df- degrees of freedom; LBM %- Lean body mass as a
percentage of total body mass; Ave- Average; T- tumor; N- lymph node; M- metastatic; Txscourses of treatments; * p < 0.05, o p < 0.10
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Table 3: Final clinical predictors of muscular gene expression
Model Formula F-Statistics for Model Fit,
By Dimension
(D1, D2, D3) ~ Patient Group D1: 0.3
D2: 6.9

Pillai’s Trace

Wilk’s Lambda

(p-value)

(p-value)

0.506

0.522

(0.044) *

(0.020) *

0.744

0.401

(0.052) o

(0.049) *

D3: 0.4
(D1, D2, D3) ~ Patient Group D1: 0.7
+ Serum Albumin D2: 3.5
D3: 2.1

D1-D3- individual dimensions of RNA-sequencing data as 3-dimensional dissimilarity matrix;
* p < 0.05, o p < 0.10
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CHAPTER 4: Causal mediation analysis of muscle wasting on the muscle fatigue
response to experimentally-induced breast cancer
A commonly accepted dogma in the field of cancer cachexia research is the assumption
that the muscle dysfunction that occurs in cancer patients is entirely a results of muscle
atrophy. This article utilized the statistical technique of causal mediation analysis to
determine whether the increased fatigability exhibited in two mouse models of BC is
mediated by muscle atrophy. These models included the PDOX model, which exhibits
increased fatigability in the absence of muscle wasting, and the EO771 orthotopic
syngeneic model, which exhibits increased fatigability in all mice but with varying
degrees of atrophy. Here, we show that muscle atrophy is likely not a mediator of the
increased fatigability exhibited in these mouse models.
In this project, I independently carried out the statistical analysis, made several of the
figures, and significantly contributed to the manuscript text.
This article is currently under review at PLOS ONE as of April 24, 2020.
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ABSTRACT
Background: Skeletal muscle fatigue is often considered to be linked to muscle
wasting in patients with cancer and in experimental models of cancer. The purpose of
this project was to utilize the statistical technique of causal mediation analysis (CMA) to
determine whether muscle wasting is a confounding mediator of muscle fatigue in
response to breast tumor growth. We tested the hypothesis that breast tumor growth in
experimental mice has a direct effect on muscle fatigue that is not mediated by muscle
wasting.
Methods: Mammary tumors were induced in immunocompetent female C57BL/6 mice
using a syngeneic tumor cell line (E0771) and in immunocompromised female NSG
mice using breast cancer patient-derived orthotopic xenografts (BC-PDOXs). Muscle
fatigue of the extensor digitorum longus (EDL) muscle was tested ex vivo. Four
different models of causal mediation analysis (CMA) were used to calculate the average
direct effects (ADE) of tumor growth on muscle fatigue and the average causal mediator
effects (ACME) of muscle mass on muscle fatigue in our breast cancer models.
Results: Significant ADEs of tumor growth on muscle fatigue were observed in BCPDOX mice and E0771 tumor-bearing mice. None of the CMA models tested showed
significant ACMEs of muscle mass on fatigue in response to breast tumor growth.
Conclusions: Our data support the hypothesis that muscle fatigue in mouse models of
breast cancer occurs as a direct effect of tumor growth and that muscle wasting is likely
not a mediator of this response. Considering the data in our study, we propose that the
criteria used to diagnose cachexia in patients with breast cancer be reexamined to
differentiate between skeletal muscle fatigue and skeletal muscle wasting.
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INTRODUCTION
Cancer is associated with peripheral toxicity, in which tissues and organ systems
adjacent to and distant from the primary tumor can be affected by tumor cell
proliferation, tumor growth, and/or the body’s physiological responses to this stressor [1,
2]. Skeletal muscle is one of the organ systems that can respond to tumor growth, with
different tumor types inducing differing responses in skeletal muscle, including varying
degrees of muscle wasting and muscle dysfunction [3]. The term cancer cachexia has
been used to describe these tumor-induced alterations in skeletal muscle over many
millennia [4]. Despite these long standing observations, cancer cachexia currently lacks
a universally accepted set of clinical parameters for diagnosis in patients. Importantly,
this lack of consensus on what constitutes cachexia has hindered the development of
therapeutic strategies to treat the condition. Cachexia remains a clinically relevant
medical issue, is estimated to account for up to 20% of cancer mortality and is
associated with reduced tolerance to tumor-directed therapies [5].
A defining characteristic of cancer cachexia is the loss of body weight, comprised
primarily of skeletal muscle and adipose tissue, associated with tumor growth [3, 5].
Muscle weakness is a symptom of muscle mass loss, as smaller muscles produce less
force (i.e. decreased maximal strength). This has led to the dogma that cancer-induced
muscle dysfunction is linked to muscle wasting. However, the muscle weakness or
decreased maximal strength that results from muscle wasting is different from muscle
fatigue, which can be defined as a decrease in muscle force due to repeated
contractions or extended periods of exertion, and can occur in the absence of muscle
wasting [6, 7]. Recently, Vanhoutte et al. [8] analyzed differences in overall survival
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(OS) when patients were diagnosed with cachexia using two separate sets of criteria.
In one set of criteria, there is a reliance on the percentage of body weight loss, changes
in body mass index (BMI) and changes in appendicular skeletal muscle index [9]. In the
second set of criteria, factors such as inflammation, muscle fatigue, and decreased
muscle strength were assessed in addition to the percentage of body weight loss [10].
The study supported decreased survival for patients diagnosed with cachexia,
regardless of the set of criteria utilized. However, the study also demonstrated that
weight loss alone had little significant impact on survival curves, while also showing a
prognostic benefit for more inclusive criteria for diagnosing cachexia [8]. While the goal
of these studies was to provide general criteria that could be applied to patients with
varying cancer diagnoses, patient responses often vary significantly among different
tumor types. Therefore, an understanding of the clinical implications of different cancer
types on skeletal muscle mass and function is required in order to develop effective
therapies specific to the cancer type.
The working hypothesis that our laboratory has been actively working on (REFs)
is that breast cancer is associated with greater muscle fatigue, a response that is
independent of muscle wasting. A significant percentage of patients with breast cancer
report fatigue [11-13], and our data in two different mouse models of breast tumor
growth support this hypothesis [14, 15]. Specifically, growth of breast cancer patientderived orthotopic xenografts (BC-PDOXs) in immunocompromised mice induced a
greater rate of muscle fatigue that occurred in the absence of muscle wasting [15].
Additionally, growth of murine syngeneic breast tumors in C57BL/6 mice was
associated with a greater rate of muscle fatigue that occurred with varying degrees of
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muscle wasting [14]. Therefore, the mechanisms promoting muscle fatigue during
tumor growth are likely different from the mechanisms contributing to muscle wasting
during tumor growth.
The purpose of this project was to utilize the statistical technique of causal
mediation analysis (CMA) to determine if muscle wasting is a mediator of the muscle
fatigue response to breast tumor growth. CMA is a statistical technique that allows for
the unbiased quantification of whether a confounding mediator contributes to the
observed responses to an experimental intervention [16-18]. We tested the hypothesis
that breast tumor growth has a direct effect on muscle fatigue that is not mediated by
muscle wasting in experimental mice. Specifically, we wanted to calculate the average
direct effects (ADE) of breast tumor growth on muscle fatigue and the average causal
mediator effects (ACME) of muscle mass on muscle fatigue in two breast tumor models.
Analyses were completed in these different murine models to specifically compare
shorter periods of tumor growth to longer durations (i.e. 4 weeks vs. 24 weeks) as well
as the species of tumor grown in the models (i.e. mouse tumor vs. human tumor). The
data support our hypothesis, that muscle fatigue in murine breast cancer occurs as a
direct effect of tumor growth and that muscle mass is likely not a mediator of this
response. Considering the data in our study, we propose that the criteria used to
diagnose cachexia in patients with breast cancer be reexamined to differentiate
between skeletal muscle fatigue and skeletal muscle wasting, and consider how each
uniquely influences patients’ quality of life and overall survival.
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METHODS
Previously published data. For this study, we utilized existing muscle fatigue and
muscle mass data in two different models of breast tumor growth in experimental mice.
Complete data for skeletal muscle responses to E0771 tumor growth in mice can be
found in Bohlen et. al. [14] and Wilson et. al. [15], and complete data for skeletal muscle
responses to BC-PDOX tumor growth in mice can be found in Wilson et. al. [15]. In our
original publications using the E0771 tumor cell line, tumor-bearing mice were combined
into a single tumor group. In this current study, we performed CMA with the mice
combined into one tumor group as well as separated by the presence of tumor
ulceration. Although we do not know the reason for the differing tumor phenotypes in
response to E0771 tumor cell implantation, we observed differences in body mass at
the time of euthanasia, providing rationale for analyzing these groups separately. The
muscle fatigue and muscle mass data in mice with non-ulcerated and ulcerated E0771
tumors have not been previously published.
Mouse models of mammary tumor growth.
E0771 syngeneic mammary tumor growth. Mammary tumors were induced in female
mice using a syngeneic tumor cell line (E0771) in C57BL/6 mice, as previously
described [14, 15]. Female C57BL/6 mice (stock #: 000664) were purchased from The
Jackson Laboratory (n=30) and randomly assigned to three groups: control mice (Con;
n=8), mice that were euthanized following 2 weeks of tumor growth (2WK, n=5), and
mice that were euthanized following 4 weeks of tumor growth (4WK, n=17). Preliminary
studies were completed, in which it was determined that the duration from tumor cell
implantation to maximal tumor burden was 4 weeks (data not shown). After 4 weeks of
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tumor growth, mammary tumors presented as a heterogeneous mix of ulcerated and
non-ulcerated tumors. Therefore, the 4WK group was further divided into mice that
developed an ulcerated tumor (n=7) and mice that developed a non-ulcerated tumor
(n=10) for final analyses.
BC-PDOX mammary tumor growth. BC-PDOX mice were produced by implanting
freshly collected breast tumor tissue into the cleared mammary fat pad of NOD.CGPrkdscid Il2rgtm1 Wjl/SzJ/ 0557 (NSG) mice as previously described [15, 19, 20]. Each
BC-PDOX model was authenticated with the original patient’s biopsy using genomic
DNA and short tandem repeat based PCR amplification (Arizona University Genomics
Core Facility, Tucson, AZ, USA). Routine human and mouse pathogen screening was
performed on original and passaged tissue by Charles River Laboratories (Wilmington,
MA, USA). RNA sequence and whole exome analysis of the original biopsy and
passage 1 BC-PDOX further confirmed relatedness of samples and stability of genomic
alterations identified in BC patient and the corresponding PDOX. Expression of
clinically relevant BC receptors correlated with the original BC biopsy. BC-PDOX mice
(n=8; age = 23 ± 6 weeks) were compared to non-tumor NSG mice (n=6; age = 11 ± 1
weeks) as well as NSG mice that received human BC-PDOXs which did not engraft
(Surgical-Con; n=5; age = 51 ± 16 weeks). Clinical information on specific BC-PDOXs
utilized, including tumor subtype and tumor stage classification, were previously
published [15]. Mice were housed in the animal vivarium at West Virginia University in
an ABSL-2 level room following tumor cell or BC-PDOX implantation, at 22°C under a
12:12-h light-dark cycle and received food and water ab libitum. Tumor growth was
assessed by veterinary staff based on the approved WVU Tumor Development and
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Monitoring Policy. The average duration from tumor implantation to maximal tumor
burden was 133 ±71 days (range: 39-265 days). All animal experiments were approved
by the Institutional Animal Care and Use Committee at West Virginia University.
Ex vivo muscle physiological analysis. Muscle contractile properties were examined
in the extensor digitorum longus (EDL) muscles of experimental mice using methods as
previously described [14, 15, 21-24]. Briefly, muscles were transferred to an
oxygenated tissue bath containing Ringer’s solution (100 mM NaCl, 4.7 mM KCl, 3.4
mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM HEPES, and 5.5 mM D-glucose)
maintained at 22°C. Muscle length was adjusted to optimal length (Lo), which produced
the maximal twitch response. With the muscle set at Lo, muscle fatigue was analyzed
using a repeated stimulation protocol lasting 6 min and consisting of repeated 40Hz
tetanic trains that occurred once every second and lasted 330 ms [25]. LabChart
software V7 (ADInstruments, RRID: SCR_001620) was used to obtain the area under
the fatigue curve (AUC), which was used as a measure of total force produced during
the fatigue protocol. The AUC value and corresponding EDL muscle mass for each
muscle were used in CMA calculations.

Statistical Analyses.
Causal Mediation Analysis. The primary method of analysis in the present study was
CMA, using a model-based inference strategy as previously described [26]. Briefly, a
model-based CMA requires the fitting of two separate linear regression (LR) models to
the data: a “mediator model,” where the mediator variable (muscle mass) is regressed
on the intervention variable (tumor), and an “outcome model,” where the outcome
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variable (muscle fatigue, presented as AUC) is regressed on the intervention variable
while controlling for the mediator (Figure 1A). Additional covariates can be added to
the LR models to control for their effect on the mediator and/or the outcome variable.
These LR models were then passed to the mediate function of the “mediation” Rpackage for calculation of ACME and ADE and their associated uncertainty estimates
over a number of simulations. In this analysis, we utilized 10,000 simulations per CMA
for calculation of quasi-Bayesian 95% confidence intervals. Standard multiple
regression was conducted in R v3.5.0 [27]. Two R packages, “DescTools” v0.99.28 [28]
and “olsrr” v0.5.2 [29], were utilized for appropriate assumption checking after fitting
linear models. Assumptions tested include the normality of dependent variables,
absence of univariate outliers, non-multicollinearity, homoscedasticity, and absence of
regression outliers. No assumptions were found to be violated. Models tested are
summarized as follows:
PDOX Model Summaries (Figure 1B)
CMA 1 (Mediator LR): EDL mass ~ subgroup (naive, surgical control, tumor-bearing)
CMA 1 (Outcome LR): AUC ~ EDL mass + subgroup
CMA 2 (Mediator LR): EDL mass ~ group (control, tumor-bearing) + age in weeks
CMA 2 (Outcome LR): AUC ~ EDL mass + group + age in weeks
E0771 Model Summaries (Figure 1C)
CMA 3 (Mediator LR): EDL mass ~ tumor type (no tumor, ulcerated, non-ulcerated)
CMA 3 (Outcome LR): AUC ~ EDL mass + tumor type
CMA 4 (Mediator LR): EDL mass ~ group (control, tumor-bearing) + tumor ulceration
status
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CMA 4 (Outcome LR): AUC ~ EDL mass + group + tumor ulceration status

Descriptive and comparative statistics. Data are presented as means ± SD. For E0771
experiments, tumor volume, body mass, AUC and muscle mass were analyzed using a
one-way analysis of variance (ANOVA) for 4 experimental groups (Con, 2WK, 4WK
non-ulcerated, 4WK-ulcerated). A two-way ANOVA with Tukey’s post-hoc test was
used to analyze fatigue curves, comparing force output over time during the 6-minute
fatigue protocol. Statistical inferences were based on two-sided tests and the null
hypothesis was rejected when p<0.05.
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RESULTS
Causal mediation analysis in the BC-PDOX model. In our original publication,
skeletal muscles from BC-PDOX mice fatigued at a greater rate than both naïve control
mice and surgical control mice, and there were no significant differences in muscle
mass of the tested skeletal muscle [15]. Data presented in Figure 2 represent the
mean and 95% confidence intervals for the ADE and ACME tested. In the four different
CMA models we tested, there were significant values for the direct effect (ADE) of tumor
growth on the muscle fatigue response, with a negative effect size in all cases,
indicating that tumor growth results in a decreased AUC value that reflects increased
fatigability. However, muscle mass was not a significant mediator (ACME) of the muscle
fatigue response (Table 1). The ADE was strongest when comparing the BC-PDOX
mice and the naïve control mice (Figure 2A), while the comparison of BC-PDOX mice
to surgical controls reached a p-value equal to 0.05 (Figure 2B). When both control
groups were combined into a single group, the ADE was highly significant (Figure 2C).
When the age of the experimental animals at euthanasia was used as a covariate in the
CMA model, the ADE was also highly significant (Figure 2D). No model tested showed
a significant ACME of muscle mass. Collectively, these data demonstrate that tumor
growth in the BC-PDOX mouse model directly contributes to the muscle fatigue
response and that muscle mass is likely not a mediator of muscle fatigue in this mouse
model of breast cancer.

Skeletal muscle responses to E0771 mammary tumor growth. One million E0771
tumor cells were implanted into the mammary fat pads of female wild type C57BL/6

94
mice, as previously described [14]. Following 4 weeks of tumor growth, both nonulcerated tumors and ulcerated tumors were observed in experimental mice (Figure
3A). The volume of these tumors at the time of euthanasia differed significantly, such
that 2WK tumors averaged 397.3 mm3 ± 33.8, 4WK non-ulcerated tumors averaged
3927 mm3 ± 571.3, and 4WK ulcerated tumors averaged 1830 mm3 ± 405.8 (Figure
3B). Upon removal of the tumor, the body weight of Con, 2WK and 4WK non-ulcerated
mice were not significantly different. However, 4WK ulcerated mice weighed 19.6%,
17.4%, and 11.6% less than Con, 2WK, and 4WK non-ulcerated mice at the time of
euthanasia, respectively (Figure 3C). When body weight was tracked from the time of
tumor cell implantation to euthanasia, 2WK mice gained 3.0%, 4WK non-ulcerated mice
lost 8.6% and 4WK ulcerated mice lost 17.4% body weight (Figure 3D). Therefore, we
were able to induce cachexia (i.e. loss of body weight) in wild type mice in response to 4
weeks of E0771 tumor growth and ulcerated tumors had a more dramatic effect on
overall body weight loss than non-ulcerated tumors, despite a smaller tumor volume.
Muscle fatigue was analyzed using a repeated stimulation protocol, with the
fatigue index calculated as the percent difference of each contraction from the initial
contraction of the protocol. When the fatigue index curve was plotted, a clear pattern
emerged with respect to the duration of tumor exposure. There were no differences in
the fatigue curves of EDL muscles from Con and 2WK mice. However, the fatigue
curves of EDL muscles from both 4WK non-ulcerated and 4WK ulcerated mice were
shifted down and to the left compared to Con and 2WK, demonstrating a faster rate of
force loss with repeated contractions. This shift occurred during the first 80 seconds of
the fatigue protocol (Figure 3E). Additionally, there was a significantly lower AUC when
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comparing the fatigue curves of EDL muscles from mice exposed to 4 weeks of tumor
growth compared to the AUC from Con mice (Figure 3F). Mass of the EDL muscle was
significantly lower following 4 weeks of tumor growth, compared to control mice and
2WK mice. The loss of EDL muscle mass with tumor growth was not different between
4WK non-ulcerated and 4WK ulcerated mice (Figure 3G).

Causal mediation analysis in the E0771 model. Data presented in Figure 4
represent the mean and 95% confidence intervals for the ADE and ACME tested. In
CMA models tested, there were significant values for the ADE of tumor growth on the
muscle fatigue response. However, muscle mass was not a significant mediator of the
muscle fatigue response in any model tested (Table 1). The ADE was strongest when
comparing the 4WK non-ulcerated mice and control mice (Figure 4A), while the
comparison of 4WK ulcerated mice to control mice reached a p-value of 0.05 (Figure
4B). When both tumor groups were combined into a single group, the ADE was highly
significant (Figure 4C). When the tumor ulceration phenotype was used as a covariate
in the CMA model, the ADE was also highly significant (Figure 4D). Thus, tumor
growth in the syngeneic E0771 tumor xenograft model directly contributes to muscle
fatigue and muscle mass is likely not a mediator of muscle fatigue in this mouse model
of breast cancer.
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DISCUSSION
The purpose of this study was to utilize the statistical technique of CMA to
determine if muscle wasting is a mediator of the muscle fatigue response to breast
tumor growth. We found that breast tumor growth in mice contributes to muscle fatigue
directly, and this response is likely not mediated by muscle wasting. These conclusions
are based on data acquired in two separate mouse models of breast cancer: 1) the BCPDOX model in which muscle mass was not significantly different between tumorbearing and control mice after an average of 24 weeks of tumor growth; and 2) the
E0771 syngeneic xenograft model in which muscle mass was statistically different
between tumor-bearing mice and control mice after 4 weeks of tumor growth. Multiple
CMA models were analyzed in each breast cancer model to test for mediator effects of
muscle wasting as well as covariates within each breast cancer model. The strength of
CMA is the ability to obtain “unbiased estimates of the part of the effect of an
intervention that is mediated through a specific variable” [16]. In the current study, the
“effect” was muscle fatigue, the “intervention” was breast tumor growth, and the
“mediator variable” was muscle mass.
In the PDOX model, we anticipated that muscle mass would not be a significant
mediator of muscle fatigability because muscle mass was not significantly affected in
tumor-bearing animals. Unsurprisingly, muscle mass was not found to be a significant
mediator of muscle fatigability in this model (p = 0.41). Even if this result were
statistically significant, the effect size of -152 is less than 10% of tumor’s direct effect on
muscle fatigability of -1660 (p < 0.0001), indicating that even if muscle mass were a
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mediating factor, the proportion of the effect attributable to change in muscle mass is
very small.
In the EO771 model, many of the mice did exhibit significant muscle atrophy and
body weight loss, particularly in mice with ulcerated tumors. It would therefore be more
likely for this model to show a relationship between muscle mass and muscle
fatigability. However, muscle mass was not found to be a significant mediator of muscle
fatigability (p = 0.61). Even if this result were statistically significant, the effect size of
+168 is in the opposite direction of, and much smaller than, tumor’s effect on fatigability,
-2990 (p < 0.0001). This means that if muscle mass were a mediating factor in this
model, muscle atrophy would be protecting against fatigue, not contributing to it. An
alternative interpretation of these data could be that muscle fatigue is protecting against
muscle atrophy.
The strength of CMA is the ability to obtain “unbiased estimates of the part of the
effect of an intervention that is mediated through a specific variable” [16]. In the current
study, the “effect” was muscle fatigue, the “intervention” was breast tumor growth, and
the “mediator variable” was muscle mass. Since the CMA was not statistically
significant for the mediator variable in the two breast tumor models utilized, but was
significant for a direct effect of tumor growth on fatigue, we concluded that muscle
wasting was not a mediator of the muscle fatigue observed in response to breast tumor
growth. This observation is strengthened by the use of two different mouse models of
breast cancer with varying durations of tumor growth. However, our enthusiasm for this
conclusion is slightly tempered by the fact that it is based on the specific methodology
our laboratory utilizes to assess muscle fatigue (i.e., ex vivo muscle stimulation) [14, 15,
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21-24, 30]. Further analyses using additional models of fatigue in experimental animals
and humans are warranted, to verify and validate these conclusions.
Evidence for negative effects on skeletal muscle mitochondria have been
reported in experimentally-induced cancer, and this is often associated with body weight
loss and muscle wasting. A recent study demonstrated mitochondrial dysfunction in
muscles from mice with syngeneic colon adenocarcinoma xenograft tumors, in addition
to a 20% loss of body weight and lower skeletal muscle masses [31]. Supporting this
effect in breast cancer, Gilliam et al [32] show a reduced mitochondrial respiration rate
following breast tumor growth and chemotherapy in mice. Interestingly, recent studies
suggest the possibility that mitochondrial dysfunction occurs prior to the onset of muscle
wasting [33, 34]. This suggests a temporal response to tumor growth within skeletal
muscle may exist, in which mitochondrial function may be susceptible to the early
stages of tumor growth, followed by muscle wasting in the later stages of disease. In
the E0771 breast tumor model, we show that 4 weeks of tumor growth is associated
with lower body mass and skeletal muscle mass in addition to a greater rate of muscle
fatigue [14].However, data in the BC-PDOX model system are counter to this
hypothesis, since we observed greater muscle fatigue in the absence of muscle wasting
in mice following 24 weeks of tumor growth and with positive metastases [15].
Therefore, while mitochondrial dysfunction may be a common mechanism between a
number of cancer models [31], this dysfunction is not necessarily mechanistically linked
to the onset or occurrence of muscle wasting.
In a recent review on the topic of cancer cachexia, patients diagnosed with
breast cancer were identified as having the second lowest prevalence of cachexia and
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the lowest average weight loss among patients diagnosed with eight different cancer
types [3]. Despite this relatively low percentage of body weight loss, a significant
percentage of patients with breast cancer report fatigue, which can occur in response to
both tumor growth itself and cancer-associated therapies [35-37]. In an attempt to
determine the molecular alterations associated with the skeletal muscle responses in
patients with breast cancer, we analyzed the global transcriptional profile of skeletal
muscle from early stage non-metastatic breast cancer patients as well as from BCPDOX mice [14, 15]. A subset of concordantly dysregulated genes in muscle from
humans and mice exposed to human breast tumors was identified, and these genes
predicted changes in metabolism as well as mitochondrial function. Multiple
bioinformatics platforms predicted dysregulation of pathways involved in peroxisome
proliferator activated receptor (PPAR) signaling, glucose/energy metabolism, regulation
of lipid metabolism, and ATP generation via the electron transport chain. These
transcriptional changes were further supported by the skeletal muscle functional data in
BC-PDOX mice showing a greater rate of muscle fatigue following breast tumor growth.
A greater rate of fatigue occurred despite no significant differences in the muscle mass
of the EDL muscle following tumor growth in this model [15]. Therefore, the BC-PDOX
model recapitulates the clinical observation of breast cancer-induced muscle fatigue in
the absence of muscle wasting. Clinicians should be aware that patients with breast
cancer may not have dramatic changes in body weight and/or muscle mass during
tumor growth or tumor-directed therapies. However, this does not necessarily imply that
muscle dysfunction, in the form of persistent fatigue, is not adversely affecting the
quality of life of the patient. Based on our transcriptional data in human patients,
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skeletal muscle is responding at the early stages of breast tumor growth, and these
transcriptional changes would predict the dysregulation of pathways associated with
muscle fatigue [15].
Previous data from our laboratory supports an association of greater IL-15 with
increased mitochondrial density in skeletal muscle [23, 38-40]. Furthermore, in vitro
data from our laboratory [41] and others [42] supports the direct effect of IL-15 binding
in the stimulation of pathways upstream of mitochondrial biogenesis within skeletal
muscle. We utilized this mechanism of action in a breast cancer model by inducing
mammary tumors in transgenic mice overexpressing IL-15 in skeletal muscle, which
was then actively secreted into the circulation [43]. In our model system, E0771
mammary tumor growth in IL15TG mice was associated with a rescue of muscle fatigue
following 4 weeks of tumor growth. However, there was approximately 23% loss of
muscle mass in IL15TG mice exposed to tumor growth, compared to IL15TG mice not
exposed to tumor growth. Therefore, in this model system, we were able to attenuate
the expected increase in muscle fatigability induced by E0771 mammary tumor growth,
despite a significant loss of muscle mass. Therefore, these data suggest that although
experimentally-induced breast cancer is associated with muscle atrophy in this model,
the mechanisms that mediate muscle wasting and muscle fatigue are independent of
one another since we could rescue the greater amount of fatigue in atrophied muscles.
A limitation of our study, which we identified above, is the utilization of only one
method to test muscle fatigue. In our ex vivo preparation, the EDL muscle is electrically
stimulated in a tissue chamber that contains Ringers solution that is temperature
controlled and oxygenated. This model represents the inherent contractile and fatigue
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properties of the muscle, since we can eliminate any effects of altered blood flow or
nervous system input to the muscle during fatiguing contractions. Despite these
caveats, the conclusions of this current study should be confirmed in additional animal
models of fatigue (i.e., in situ muscle stimulation; whole animal exercise) to verify and
validate our conclusions. An additional limitation of this study is the exclusive use of
female mice. While the use of female mice for the study of breast cancer is justified by
the 100x greater incidence of this disease in women compared to men [44], this limits
the conclusions we can make on the overall role of sex in muscle fatigue. Skeletal
muscle tissue is one of the top three most sexually dimorphic tissues in humans, along
with adipose tissue and mammary tissue [45]. For example, men lose more weight in
response to tumor growth, lose more skeletal muscle mass, and have approximately
double the incidence of cachexia as women with cancer [46, 47]. Furthermore, in men,
the loss of muscle function correlates with loss of muscle mass, but this is not the case
in women. In other words, women experience muscle dysfunction without a
commensurate loss of muscle mass [48]. This observation can be attributed to multiple
potential mechanisms, including a recently described phenomenon whereby women
with cancer exhibit a significant infiltration of non-contractile tissue into skeletal muscle,
significant metabolic differences between males and females, and/or differences in
hormonal concentrations in males and females [7]. Future studies should include male
mice to address the effects of breast cancer in males as well as the effect of sex on
muscle fatigue and muscle wasting in response to breast tumor growth.
In conclusion, our CMA analysis provides evidence that muscle fatigue, in
experimentally-induced breast cancer, occurs as a direct response to breast tumor
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growth and is likely not mediated by changes in muscle mass. This finding is consistent
with observations in patients with breast cancer, since fatigue is a commonly reported
symptom while body weight loss is comparatively low in this population [3]. Therefore,
the criteria used to define and diagnose cachexia in breast cancer patients should be
reexamined to differentiate muscle fatigue and muscle wasting. The recognition that the
underlying mechanisms contributing to muscle fatigue and muscle wasting are different,
and that muscle fatigue may occur in these patients without concomitant body weight
loss, is a first step in the ability to design and implement therapies to improve the quality
of life of patients with breast cancer.
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FIGURES AND FIGURE LEGENDS
Figure 1: Causal mediation analysis models of muscle wasting and muscle
fatigue in response to breast tumor growth.
Figure 1
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(A) Representative CMA diagram depicting the mediator linear regression and
outcome linear regression models tested. (B) CMA Model 1 was generated to test the
direct effects of BC-PDOX tumor growth on muscle fatigue (thick arrow), and the
mediator effects of muscle mass the muscle fatigue response to tumor growth (blue,
thin arrows). CMA Model 2 included the age of control mice as a covariate (yellow
arrows). (B) CMA Model 3 was generated to test the direct effects of E0771 tumor
growth on muscle fatigue (thick arrow), and the mediator effects of muscle mass the
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muscle fatigue response to tumor growth (blue, thin arrows). CMA Model 4 included the
presence of a tumor ulceration as a covariate (yellow arrows).

Figure 2: Causal mediation analysis in BC-PDOX mice.
Figure 2
A

B

C

D

Graphical representation of the estimate and 95% confidence interval for the Total
Effect, the Average Direct Effect (ADE) and the Average Causal Mediation Effect
(ACME) for all CMA models tested. The direct effect of tumor growth on muscle fatigue
was highly correlated with the total effect, while there was no significant mediator effect
of muscle mass in comparing naïve control mice (A) or surgical control mice (B) to BCPDOX mice. Similar results were obtained when both control groups were combined
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into a single group for comparison to BC-PDOX (C), and when the age of the two
control groups was used as a covariate in the analysis (D). Data presented as the
mean and 95% confidence intervals for the ADE and ACME tested in these models.

Figure 3: E0771 tumor growth in C57BL/6 mice.
Figure 3
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(A) Following 4 weeks, tumors presented with a mixture of non-ulcerated and ulcerated
tumors. (B) Tumor volume progressively increased through 4 weeks of growth, with
non-ulcerated tumors being larger than ulcerated tumors at the time of euthanasia. (C)
Body mass at euthanasia, following the removal of the mammary tumor, was
significantly different in the mice with ulcerated tumors compared to all other groups.
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(D) Mice with ulcerated tumors lost a greater percentage of body mass through the 4
weeks of tumor growth, compared to all other groups. (E) The fatigue index curves of
EDL muscles from mice with a non-ulcerated tumor and an ulcerated tumor were shifted
down and to the left compared to fatigue index curves of EDL muscles from control mice
and mice following 2 weeks of tumor growth, demonstrating greater muscle fatigability.
(F) The area under the EDL fatigue curve, indicative of the total amount of force
produced during the fatigue protocol, was less in mice with a non-ulcerated tumor and
an ulcerated tumor compared to control mice. (G) EDL absolute muscle mass and
mass normalized to body mass. *, p<0.05; **, p<0.001; ***, p<0.0001.
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Figure 4: Causal mediation analysis in E0771 tumor-bearing mice.
Figure 4

A

B

C

D

Graphical representation of the estimate and 95% confidence interval for the Total
Effect, the Average Direct Effect (ADE) and the Average Causal Mediation Effect
(ACME) for all CMA models tested. The direct effect of tumor growth on muscle fatigue
was highly correlated with the total effect, while there was no significant mediator effect
of muscle mass in comparing control mice to mice with non-ulcerated tumors (A) or
mice with ulcerated tumors (B). Similar results were obtained when both tumor groups
were combined into a single group for comparison to control (C), and when the
presence of tumor ulceration was used as a covariate in the analysis (D). Data
presented as the mean and 95% confidence intervals for the ADE and ACME tested in
these models.
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TABLES
Table 1: Summary of Causal Mediation Analysis Models
Model

Comparison

ACME Estimate

ACME

ADE Estimate

ADE

(Muscle Mass)

p-value

(Fatigue)

p-value

(95% CI)
BC-

All Control vs. PDOX

PDOX

(age as covariate)

E0771

(95% CI)

-152 (-667, 176)

0.41

-1660 (-2490, -822)

<0.0001***

All Control vs. PDOX

-150 (-655, 167)

0.42

-1650 (-2500, -831)

<0.0001***

Naïve Control vs. PDOX

-147 (-664, 171)

0.43

-2080 (-2940, -1233)

<0.0001***

Surgical Control vs. PDOX

-170 (-717, 156)

0.38

-886 (-1767, 7)

0.05

Control vs. All Tumor

168 (-407, 1053)

0.61

-2990 (-4760, -1226)

<0.0001***

Control vs. All Tumor

782 (-304, 2041)

0.16

-2403 (-3855, -951)

0.001**

Control vs. Ulcerated

548 (-928, 2169)

0.47

-1768 (-3601, 23)

0.05

Control vs. Non-ulcerated

315 (-600, 1349)

0.48

-2513 (-3979, -194)

0.001**

(tumor ulceration as
covariate)
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CHAPTER 5: Breast cancer-associated skeletal muscle mitochondrial dysfunction and
lipid accumulation is reversed by PPARG
The work described in the previous three chapters clearly implicates the peroxisomeproliferator activated receptors (PPARs) in the pathophysiology of skeletal muscle
dysfunction in breast cancer (BC) and in animal models of BC. This work expands on
those observations by transitioning to an in vitro model system to identify metabolic
alterations induced in skeletal muscle directly by BC-derived factors and to determine
whether the PPAR proteins are indeed involved in the response. Here, we show
unequivocally that BC cells secrete a factor that represses the transcriptional activity of
PPARs, downregulation of PPARG target genes, mitochondrial dysfunction, and
accumulation of lipid within differentiated muscle cells. The PPARG agonist drug
rosiglitazone was able to rescue BC-induced lipid accumulation, but did not rescue
effects of BC-derived factors on PPAR-mediated transcription or mitochondrial function,
but expression of exogenous PPARG protein reversed both BC-induced mitochondrial
dysfunction and lipid accumulation. Collectively, these data indicate that BC-induced
lipid metabolism and mitochondrial function occur via different mechanisms that are
both related to PPAR signaling.
This article is almost entirely my independent work. I developed the protocols for the in
vitro model system for use in our laboratory and independently collected all of the data
presented herein. I was also the main contributor to the manuscript text.
This article is currently under review at Journal of Biological Chemistry as of April 10,
2020.
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ABSTRACT
The peroxisome-proliferator activated receptors (PPARs) have been previously
implicated in the pathophysiology of skeletal muscle dysfunction in women with breast
cancer (BC) and in animal models of BC. Here, we sought to describe the metabolic
alterations induced in skeletal muscle by BC-derived factors in an in vitro conditioned
media (CM) system and hypothesized that BC cells secrete a factor that represses
PPAR-gamma (PPARG) expression and its transcriptional activity, leading to
downregulation of PPARG target genes involved in mitochondrial function and other
metabolic pathways. We found that BC-derived factors repress PPAR-mediated
transcriptional activity without altering protein expression of PPARG. Further, we show
that BC-derived factors induce significant alterations in skeletal muscle mitochondrial
function and lipid metabolism, which are rescued with exogenous expression of
PPARG. The PPARG agonist drug rosiglitazone was able to rescue BC-induced lipid
accumulation, but did not rescue effects of BC-derived factors on PPAR-mediated
transcription or mitochondrial function. These data suggest that BC-derived factors
induce deficits in lipid metabolism and mitochondrial function via different mechanisms
that are both related to PPARG signaling, with mitochondrial dysfunction likely being
altered via repression of PPAR-mediated transcription, and lipid accumulation being
altered via transcription-independent functions of PPARG.
Keywords: breast cancer, cancer-related fatigue, peroxisome-proliferator
activated receptors, mitochondrial electron transport chain deficiencies,
myosteatosis
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INTRODUCTION
Breast cancer (BC)-associated skeletal muscle fatigue is a chronic problem among BC
survivors, being reported by a majority of patients both prior to and after receiving anticancer therapies 1-5. Recent studies show that deficits in muscle function predict shorter
survival in cancer, perhaps due to the fact that fatigue is known to reduce a patient’s
tolerance to anti-cancer therapies 3,6-10. Therefore, improving muscle function in BC
patients has the potential to improve both quality of life and survival in the most
commonly diagnosed cancer type in women.
The peroxisome-proliferator activated receptors (PPARs) are lipid sensing, ligand
activated transcription factors previously implicated in a variety of pathologies, including
cancer, atherosclerosis, Alzheimer’s disease, type 2 diabetes mellitus, and others 11-14.
These transcription factors aid in regulating whole body energy homeostasis via
regulation of genes involved in lipid metabolism and mitochondrial functions 11,15-19.
Recently, downregulation of PPAR-gamma’s (PPARG) transcriptional activity in skeletal
muscle has been identified as a potential central regulator of the increased muscle
fatigue experienced by women with BC and recapitulated in the patient-derived
orthotopic xenograft model of BC 20. However, the mechanism by which PPARG
downregulation induces muscle dysfunction has not yet been explored. We
hypothesized that BC cells secrete a factor that represses PPARG expression and its
transcriptional activity, leading to downregulation of PPARG target genes involved in
mitochondrial function and other metabolic pathways.
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METHODS
Cell culture. Cell lines utilized include EpH4-EV (immortalized normal murine
mammary epithelium), EO771 (murine luminal BC), NF639 (murine HER2/neuoverexpressing BC), HEK293 (human embryonic kidney), and C2C12 (murine
myoblasts). All cell lines were obtained from ATCC (Virginia, USA), with the exception
of EO771, which were obtained from Dr. Metheny-Barlow at Wake Forest University. All
cell lines were cultured in DMEM (Thermo Fisher, Massachusetts, USA) supplemented
with 10% heat inactivated fetal bovine serum (Atlanta Biologicals, Georgia, USA) and
penicillin/streptomycin (Thermo Fisher) at 37oC with 6% CO2.
Exogenous PPARG myogenic cell line. Lentiviral particles containing pLenti-CPPARG2-mGFP-P2A-Puro or pLenti -mGFP-P2A-Puro were purchased from Origene
(Maryland, USA). Titers were provided by the manufacturer. C2C12 cells were plated at
125,000 cells.well-1 in 24-well plates and infected with a multiplicity of infection of 75
transforming units per cell with 8 µg · mL-1 polybrene in antibiotic-free DMEM. Media
was changed 20 hours after infection. Starting 48 hours after infection, cells were
cultured in 2 µg · mL-1 puromycin for 10 days, after which cells were maintained in 0.5
µg · mL-1 puromycin indefinitely. Uninfected control cells exhibited 100% death within 3
days of puromycin selection. Second passage cells were used in Western blotting
analysis to assess expression of PPARG2 protein. All experiments with these cell lines
were conducted within 5 passages of lentiviral infection as higher passage cells lost
differentiation competence.
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Conditioned media (CM) collection. CM donor cells were plated at approximately
15% confluence in separate 10cm dishes for 48 hours. The 48-hour CM was then
removed from all cell lines using a serological pipette, centrifuged at 1,500 RPM for 10
minutes, and the supernatants were collected via decanting into new centrifuge tubes.
The collected CM was then diluted 1:3 in fresh growth media prior to application to
recipient cells. CM was always applied to recipient cells within 2 hours of collection, in
most cases within 15 minutes of collection (Figure 1A). In some experiments,
rosiglitazone (Millipore-Sigma, Massachusetts, USA) in dimethyl sulfoxide (DMSO) was
added to the diluted conditioned media to final concentrations of 10 µM rosiglitazone
and 0.1% DMSO prior to CM application to donor cells. In experiments where
rosiglitazone was used, DMSO was added to control CM to 0.1% final concentration as
a vehicle control.
Western blotting. Differentiated C2C12s were lysed in 50 mM Tris-HCl (pH 6.8) with
2% sodium dodecyl sulfate and heated to 100oC for 3 cycles of 3 minutes each with
vortexing and brief centrifugation between heating cycles. Lysates were diluted to a final
concentration of 1 µg . µL-1 in NuPAGE LDS Sample Buffer (ThermoFisher Scientific)
and 5% β-mercaptoethanol. 12 µg of total protein was loaded per well and resolved in
NuPAGE Novex 4-12% Bis-Tris Gels (ThermoFisher Scientific). Proteins were
transferred to nitrocellulose membrane, blocked for 1 hour in 1X tris-buffered saline
(TBS), 0.1% Tween20, 5% milk followed by incubation with primary antibody overnight
at 4°C in TBS-tween20 with 5% milk. Membranes were then washed 3 times in TBS +
0.1% Tween20 prior to application of appropriate secondary antibody (ThermoFisher
Scientific) for 90 minutes at room temperature, and again prior to application of Pierce
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ECL Western Blotting Substrate (ThermoFisher Scientific). Relative band intensity was
quantified using the GE Amersham Imager 600 (GE Healthcare Life Sciences,
Marlborough, MA, USA) and normalized to GAPDH. Primary antibodies included
PPARγ (#PA3-821A) and GAPDH (#2118S).
CM metabolic analyses. C2C12 cells were plated into Agilent Seahorse XF96 (Agilent
Technologies, California, USA) plates at 10,000 cells.well-1 and differentiated in 2%
horse serum (Atlanta Biologicals) in DMEM with antibiotics for 48 hours. Meanwhile,
EpH4-EV, EO771, NF639, and C2C12 cells were plated at approximately 15%
confluence in separate 10cm dishes for 48 hours. 48-hour CM, prepared as described
above, was then applied to the 2-day differentiated C2C12 cells in Seahorse assay
plates for 48 hours (n=6-12 wells per treatment condition, noted in figure legends) prior
to conducting the Agilent Seahorse XF Cell Mito Stress Test or Agilent Seahorse XF
Glycolysis Stress Test protocol according to manufacturer’s instructions, using
manufacturer’s recommended reagents.
PPAR-reporter assays. HEK293 cells were transfected with PPRE-H2b-eGFP 21
(Addgene #84393) and selected for stable construct expression to create the HEK293PPRE-H2b-eGFP (HEK-PGFP) cell line. CM donor cells were plated on D0 as
described above, and HEK-PGFP cells were plated at approximately 15% confluence
on Day 1 (D1). On D2, baseline GFP intensity was collected using the BioTek Cytation
5 Cell Imaging Multi-Mode Reader (Agilent Technologies), and subsequently 48-hour
conditioned media from HEK293, EpH4-EV, EO771, and NF639 cell lines was applied
to the 24-well plate (n=3-6 wells per treatment condition, noted in figure legends). HEKPGFP cells were then incubated in CM under normal culture conditions and GFP
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intensity was quantified 24 hours later using identical imaging settings as the baseline
measurements. Mean GFP intensity per well was calculated using Gen5 Microplate
Reader and Imager Software (Agilent Technologies), obtaining a single value per well
that represented the mean GFP intensity of all cells in the imaging field for that well.
qRT-PCR for PPAR target genes. C2C12 cells were plated at approximately 90%
confluence in 24-well plates (150,000 cells.well-1) on D0 and differentiated in 2% horse
serum (Atlanta Biologicals) in DMEM with antibiotics. On D3, differentiation media was
refreshed on the C2C12s, and CM donor cells were plated as described under “CM
collection.” On D4, media on the differentiating C2C12s was changed back to normal
growth media (10% FBS in DMEM with antibiotics). On D5, CM was collected and
applied to the differentiated C2C12 cells for 2 or 24 hours, with n=3-8 wells per
condition, as noted in figure legends. Total RNA was isolated from CM- and/or drugtreated cells using Trizol (ThermoFischer Scientific, Waltham, MA, USA) and
established methods 22. 1200 µg of cDNA was produced using Invitrogen SuperScript III
First-Strand Synthesis System (ThermoFisher Scientific) according to manufacturer’s
protocol, and relative expression of selected genes was analyzed using SYBR Green
PCR Master Mix (ThermoFisher Scientific) with the Applied Biosystems QuantStudio 6
Flex (ThermoFisher Scientific), using 60 ng cDNA per reaction. Primer efficiencies were
determined to be between 85% and 115% and relative mRNA expression was
calculated using the Pfaffl method 23 normalized to 18s rRNA. Primer3 was used to
design qRT-PCR primers (Supplementary Table 1) 24.
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qRT-PCR for mitochondrial DNA. C2C12 cells were plated at approximately 90%
confluence in 24-well plates (100,000 cells.well-1) on D0 and differentiated in 2% horse
serum in Gibco DMEM with antibiotics. Differentiation and CM application was
conducted as described under “qRT-PCR for PPAR target genes,” with CM applied for
24 hours and n=8 wells per condition. Total DNA was isolated from CM-treated cells
using the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) according to
manufacturer’s instructions. 40-60 ng of DNA in 1uL eluting buffer was used for qRTPCR using Applied Biosystemcs TaqMan Universal PCR Master Mix (ThermoFisher
Scientific) with the Applied Biosystems QuantStudio 6 Flex (ThermoFisher Scientific).
Primer-probe sets were purchased from ThermoFisher Scientific (Applied Biosystems
Gene Expression Assays, COX2 Mm03294838_g1 and 18S Mm03928990_g1).
Relative COX2 mtDNA was quantified using the ΔΔCT method normalized to 18S
gDNA.
Oil red O. C2C12 cells were plated at approximately 90% confluence in 24-well plates
(100,000 cells.well-1) on D0 and differentiated in 2% horse serum in Gibco DMEM with
antibiotics. On D2, differentiation media was refreshed on the C2C12s, and CM donor
plates were set up as described under “CM collection.” On D4, CM was collected and
applied to differentiated C2C12s, and CM donor cells were split to allow for CM to be
collected once more after 48 hours incubation. On D6, CM was again collected and was
used to refresh the CM on the recipient cells. On D7, cells were fixed in 4%
formaldehyde for 30 minutes, washed 3 times in distilled water, and made permeable
with 60% isopropanol for 10 minutes. Oil red o stock solution had been previously
suspended in 100% isopropanol and filtered using a 0.2 µm bottle-top filter. Oil red o
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stock solution was diluted to 60% in distilled water to create the working solution.
Working solution was applied to the fixed and permeable cells for 10 minutes. Cells
were washed 3x with distilled water and stored at 4oC until imaging, typically within 24
hours of staining. Images were taken using a Zeiss Axiovert 40 CFL microscope with a
Zeiss Axiocam 105 color camera, running ZEN 2.3 software. Effort was made to take
images at the center of each well to produce even illumination across images. All
images within each experiment were taken using identical imaging settings. Images
were analyzed using the countcolors package version 0.9.1 25 in R version 3.6.1 26,
quantifying the area of each image within a 50% radius from true red.
Statistical analyses, reproducibility, and rigor. Data analyses were conducted in R
version 3.6.1 26 using ggpubr version 0.2.4 27 for data visualization and most statistical
tests. Unless otherwise stated, all statistical tests used were unpaired, two-tailed t-tests
for two-group comparisons and one-way ANOVA for multi-group comparisons. When
multiple comparisons were used within an experiment, Holm-Bonferroni correction was
applied to adjust p-values. Graphs represent data from a single, independent
experiment. All experiments have been repeated at least twice with similar results, with
most experiments being repeated more than 3 times. For all box and whisker plots: the
total height of the box represent the interquartile range, the thick center line represents
the median value, and the whiskers extend to the most extreme data point that is not an
outlier. Outlier values are represented by a single dot beyond the whiskers.
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RESULTS
BC-CM represses PPARG expression and PPAR-mediated transcription
Because PPARG is downregulated in the skeletal muscle of women with BC and in
mouse models of BC 20, we first investigated the capacity of BC-derived factors to
downregulate Pparg mRNA expression in an in vitro model system. To test this, we
collected CM from BC or control cell lines and applied this CM to differentiated skeletal
muscle cells in culture (Figure 1A). Cells and large debris were removed from the
media via gentle centrifugation and decanting, and the conditioned media was diluted in
1:3 in fresh growth media to correct pH and overall nutrient content. Importantly, all CM
was applied to myotubes within 2 hours of collection to ensure that biologically active
components would not degrade or be damaged by freezing prior to application. Using
this model system, we found that CM from BC cell lines significantly downregulated
Pparg mRNA expression (Figure 1B) and several of its purported transcriptional targets
28 in differentiated skeletal muscle after as little as two hours of CM exposure,
compared to media conditioned by skeletal muscle myoblasts (Figure 1C). However, no
significant change in PPARG protein expression was detected (Figure 1D), suggesting
that the downregulation of PPARG target genes’ mRNA is due to a repression of PPARmediated transcriptional activity, rather than a down-regulation of PPARG protein
abundance. To directly address this discrepancy, we generated a reporter cell line
stably expressing a PPAR-responsive reporter construct driving expression of GFP.
Using this system, we have consistently observed a significant reduction in GFP
intensity in response to BC-CM, compared to CM from the reporter cells themselves. In
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contrast, CM from a non-tumorigenic mammary epithelial cell line does not repress GFP
expression (Figure 1E).
BC-CM induces mitochondrial dysfunction and defects in lipid metabolism
We next asked whether BC-CM induced functional alterations in differentiated muscle
cells that could be reflective of the increased muscle fatigability seen in women with BC
and BC animal models. We found that BC-CM induced substantial changes in aerobic
metabolism (Figure 2A), specifically leading to a reduction of oxygen consumed in ATP
generation (Figure 2B) with inconsistent or negative results in other aerobic parameters
across 5 independent experiments (not shown). CM from the luminal EO771 BC cell line
repressed aerobic metabolism without altering glycolytic function, while the HER2overexpressing NF639 line repressed both aerobic metabolism and glycolytic functions
(Figure 2C). This reduction in aerobic metabolism does not appear to be related to
mitochondrial biogenesis, as suggested by no alteration in mitochondrial DNA copy
number in CM-treated myotubes (Figure 2D).
Because lipotoxicity-induced mitochondrial dysfunction has been reported in various
clinical contexts 29-32, and because individuals with cancer have been shown to have
increased lipid content in muscle 33,34, we assessed intramyocellular lipid concentration
in response to BC-CM using oil red o staining and automated image quantification.
Using this methodology, we repeatedly observed a significant increase in
intramyocellular lipid staining with EO771-CM, but in no experiment did we observe an
increase in response to NF639-CM (Figures 2E – 2F).
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Exogenous PPARG expression rescues BC-CM-induced mitochondrial
dysfunction and lipid accumulation
To determine whether or not the metabolic alterations induced in skeletal muscle by BCderived factors are regulated by PPARG, we first attempted to generate stable
myogenic cell lines expressing exogenous PPARG constructs or shRNA against
PPARG using lentiviral infection and subsequent selection. Consistent with previous
reports 35, genetic modification of PPARG in C2C12 myoblasts resulted in cell lines that
rapidly lost differentiation competence, within five passages from lentiviral infection.
Despite these limitations, early passage cells expressing exogenous PPARG (Figure
3A) were used to ascertain whether PPARG is involved in the response of myotubes to
BC-derived factors. In these experiments, it was found that cells expressing exogenous
PPARG were resistant to both BC-CM-induced repression of aerobic ATP generation
(Figure 3B) as well as BC-CM-induced lipid accumulation (Figures 3C – 3D). Cells
stably expressing shRNA against PPARG lost differentiation capacity immediately after
lentiviral infection and could therefore not be used to determine if PPARG ablation
phenocopies the effect of BC-CM in the context of differentiated muscle cells.
PPARG agonist rosiglitazone rescues BC-CM-induced lipid accumulation but fails
to rescue BC-CM-induced mitochondrial dysfunction and PPAR repression
Finally, we pharmacologically targeted PPARG to overcome BC-induced mitochondrial
dysfunction and lipid accumulation, using the potent PPARG agonist rosiglitazone (rosi)
of the thiazolidinedione (TZD) drug class. Rosiglitazone did induce PPAR-mediated
transcription in the absence of BC-CM (Figure 4A), but it was unable to rescue BCCM’s repression of PPAR-mediated transcription (Figure 4B). Unsurprisingly then, this
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agonist did not rescue BC-induced mitochondrial dysfunction (Figure 4C). However,
rosiglitazone did potently repress BC-induced lipid accumulation (Figure 4D). These
data indicate that the mechanism by which rosiglitazone prevents BC-induced lipid
accumulation is independent of PPARG’s transcriptional activity, and that BC-induced
lipid accumulation is not the cause of BC-induced mitochondrial dysfunction in this
model system.
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DISCUSSION
In the present study, we have identified that BC-derived factors can significantly alter
metabolic function and PPAR activity in skeletal muscle cells without the involvement of
immune or stromal cell mediators, indicating that BC cells secrete a factor that induces
these effects. Numerous publications have characterized changes in serum contents of
women with BC, including changes in miRNAs, lipids, and proteins 36-40, though the
exact sources of many of these factors remain unknown. To our knowledge, this report
is the first showing that BC-CM induces alterations in skeletal muscle metabolic
function, with previous studies focusing on BC-CM’s effect on immune cells, fibroblasts,
endothelial cells, or normal mammary epithelium 41-46, or on transcriptional changes
induced in skeletal muscle 47.
It is well established that BC cells can regulate both local and systemic immune
functions 48,49, and that inflammatory signaling is intrinsically linked to cancer-associated
skeletal muscle wasting 50,51. Thus, a reasonable assumption is that BC’s influence on
immune cells is the cause of BC-induced skeletal muscle fatigue. This study contradicts
this assumption by showing that no immunological mediators are required for BC cells
to induce significant alterations in skeletal muscle metabolic function. This study also
contradicts recent reports of negative results in other cancer types, where CM from
cancer cells was unable to directly induce mitochondrial deficits in differentiated skeletal
muscle 52, indicating that different cancer types induce skeletal muscle dysfunction via
different mechanisms. While we cannot conclusively state that mitochondrial
dysfunction or lipotoxicity are the root causes of BC-induced skeletal muscle
dysfunction, it is reasonable to hypothesize a causal link that should be further
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investigated. Most likely, there are numerous mechanisms contributing to skeletal
muscle dysfunction that would need to be simultaneously targeted to provide symptom
control.
The mechanism by which BC cells induce metabolic dysfunction in this model system
appears to be related to signaling by the PPAR proteins, as evidenced by the rescue of
mitochondrial dysfunction and lipid content provided by exogenous expression of
PPARG. This finding provides support for the translational relevance of this in vitro
model system, as PPARG has been previously identified as a potential key regulator of
BC-induced skeletal muscle fatigue using both human data and data generated in the
patient-derived orthotopic xenograft model of BC 20,53. Additionally, this finding
illuminates potential therapeutic modalities using the numerous FDA-approved agents
that target the PPAR proteins, including drugs with various specificities for the three
PPAR isoforms. In support of this possibility, we show here that the PPARG-specific
agonist rosiglitazone completely reversed BC-CM’s effect on skeletal muscle lipid
accumulation. Interestingly, this result does not appear to be due to rosiglitazone
activating PPAR-mediated transcription, suggesting that the effect is mediated by noncanonical functions of PPARG.
While we were unable to rescue BC-induced mitochondrial dysfunction using
rosiglitazone, it is possible that pharmacological agents targeting PPAR-alpha, PPARdelta, or a combination of the three isoforms could overcome these effects of BCderived factors. Alternatively, it is possible that the mitochondrial dysfunction induced by
BC-CM is due to alteration of ligand-independent functions of PPARG, which would be
overcome by the addition of PPARG protein but not by exogenous ligand. Numerous
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reports confirm the ability of PPARG to function as a transcription factor in the absence
of ligand binding 54-57, and there is evidence of PPARG having ligand-independent
functions that are also independent of its transactivation domain 58. Pharmacological
strategies to target these unique functions could include non-TZD insulin-sensitizing
agents or epigenetic modifiers.
Mechanistically, muscle fatigue can result from a myriad of factors, but the underlying
ability of the contractile elements to maintain force production relies upon the muscle’s
ability to resynthesize ATP following stimulus. We have observed dysregulation of
metabolically significant PPAR transcriptional networks in the skeletal muscle of BCPDOX mice 20, as well as a significant reduction in ATP from mitochondria isolated from
skeletal muscle of these mice. In support of these murine observations, proteomics
analysis in the skeletal muscle of HER2+ BC patients revealed lower protein expression
of nearly every component of the mitochondrial electron transport chain and a
correspondingly lower ATP content in muscle biopsies from BC-patients of multiple
tumor subtypes (publication under review). These data clearly demonstrate
mitochondrial dysfunction in muscle of patients with BC, which will directly impact the
fatigability of skeletal muscle. The results presented herein expand on our previous
studies and suggest this metabolic dysfunction is a direct result of BC-derived factors.
Intriguingly, we demonstrate that this mitochondrial dysfunction is accompanied by
increased intracellular lipid deposition in myotubes exposed to BC-CM. Intramuscular
lipid deposition has also been observed in type 2 diabetes 59 and smoking-induced
insulin resistance 60. As the downregulation of PPARG expression and transcriptional
activity is associated with the development of insulin resistance 61 and many PPAR
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transcriptional targets are mitochondrial lipid transport proteins 28, we propose that a
decreased capacity for mitochondrial lipid import may contribute to the observed
phenotype of BC-induced lipid accumulation, which may then contribute to insulin
resistance. Finally, aberrant intramyocellular lipid deposition can in many cases
contribute to lipotoxicity characterized by the accumulation of toxic lipid intermediates
such as diacylglycerols and ceramides 62, increased production of ROS 63, and is
associated with changes in autophagic dynamics 64,65, all of which are implicated in
reduced mitochondrial function within skeletal muscle. The sum of these observations
suggest that skeletal muscle lipotoxicity in breast cancer could play a major role in the
phenotype of BC induced skeletal muscle fatigue independent of mitochondrial
dysfunction, and future studies should investigate this potential link in greater detail.
In summary, our results confirm the ability of BC-derived factors to directly alter
metabolic function in skeletal muscle cells without the involvement of other cell types.
These BC-CM-induced phenotypes in skeletal muscle could be enacted by a variety of
secreted factors, including miRNAs, exosomes, or proteins, and appears to be mediated
via signaling of the PPAR proteins, though perhaps not through their canonical functions
as ligand-activated transcription factors. Specifically, BC-derived factors have the ability
to repress the transcriptional activity of PPARG, and this effect is not due to
downregulation of PPARG protein abundance. Additionally, repression of PPARG
transcriptional activity induces mitochondrial dysfunction in muscle cells and a
deficiency in ATP supply while also being associated with greater lipid accumulation.
While PPARG protein levels are not affected in our model, basal protein expression of
PPARG is relatively low in skeletal muscle, providing an explanation for the ability of
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exogenous PPARG to rescue these phenotypes while PPARG-agonists do not (Figure
5). These results provide support for previous publications implicating the PPAR
proteins in BC-induced skeletal muscle fatigue and provide rationale for investigating
PPAR agonists to improve quality of life in survivors of BC 20,53.
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FIGURES AND FIGURE LEGENDS
Figure 1: BC-CM represses PPARG expression and PPAR-mediated transcription

138
48-hour conditioned media was collected from BC (EO771 or NF639) or control cell
lines (EpH4-EV, C2C12 or HEK293), centrifuged to pellet large debris, decanted, and
diluted in fresh complete growth media prior to application on recipient cells. Figure
created using BioRender (A). Pparg mRNA expression in 5 day differentiated C2C12s
exposed to 48-hour CM for 24 hours, quantified using qRT-PCR, nCON = 12, nEO771 = 6,
nNF639 = 5 (B). mRNA expression of PPARG target genes in 5 day differentiated C2C12s
exposed to 48-hour CM for 2 hours, quantified using qRT-PCR, nCON = 3, nEO771 = 3 (C).
Western blotting analysis of PPARG protein expression in 5 day differentiated C2C12s
exposed to 48-hour CM for 48 hours, normalized to GAPDH. Error bars represent
standard deviation of the mean (D). Quantification of GFP intensity in HEK-PGFP
reporter cells exposed to 48-hour CM, quantified at 0 and 24 hours of CM exposure.
Adjusted p-values represent Holm-Bonferroni adjusted p-values of paired t-tests, n = 8
per group (E).
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Figure 2: BC-CM induces mitochondrial dysfunction and defects in lipid metabolism

Normalized oxygen consumption rate (OCR) of 2 day differentiated C2C12 myotubes
treated with 48-hour CM for 48 hours, quantified using the Seahorse XF Mito Stress
Test. Error bars represent standard deviation of the mean, n = 10 per group (A). OCR
associated with aerobic ATP production from A (B). Extra-cellular acidification rate of 2
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day differentiated C2C12 myotubes treated with 48-hour CM for 48 hours, quantified
using the Seahorse XF Glycolysis Stress Test. Error bars represent standard deviation
of the mean, n = 12 per group, except nNF639 = 10 (C). Relative quantitation of mtCOX2
DNA in 5 day differentiated C2C12s exposed to 48-hour CM for 24 hours, normalized to
18S gDNA, n = 8 per group (D). Oil red o image quantification from 4 day differentiated
C2C12s treated with 48-hour CM for 72 hours, represented as the fraction of each
image stained red with oil red o, n = 8 per group (E). Representative images from an
independent oil red o experiment conducted under identical conditions to E, 40X
magnification (F).
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Figure 3: Exogenous PPARG expression rescues BC-CM-induced mitochondrial
dysfunction and lipid accumulation

Western blotting analysis of PPARG expression in C2C12s infected with lentiviral
particles carrying pLenti-C-PPARG2-mGFP-P2A-Puro (+PPARG2) or pLenti -mGFPP2A-Puro (CON) after 5 days of differentiation (A). OCR associated with aerobic ATP
production in 2 day differentiated CON or +PPARG2 cells exposed to 48-hour CM for 48
hours, quantified using the Seahorse XF Mito Stress Test, n = 10 per group (B). Oil red
o image quantification from 4 day differentiated CON or +PPARG2 cells treated with 48hour CM for 72 hours, represented as the fraction of each image stained red with oil red
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o, n = 6 per group (C). Representative images from the experiment quantified in C, 20X
magnification (D).
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Figure 4: PPARG agonist rosiglitazone fails to rescue BC-CM-induced mitochondrial
dysfunction and PPAR repression, but rescues BC-CM-induced lipid accumulation

Quantification of GFP intensity in HEK-PGFP reporter cells exposed to 10 uM
rosiglitazone (rosi) or DMSO (control), quantified at 0 and 24 hours of drug exposure, n
= 3 per group (A). Quantification of GFP intensity in HEK-PGFP reporter cells exposed
to 48-hour CM in the presence of 10 µM rosiglitazone, quantified at 0 and 24 hours of
CM exposure. Adjusted p-values represent Holm-Bonferroni adjusted p-values of paired
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t-tests, n = 4 per group (B). OCR associated with aerobic ATP production in 2 day
differentiated C2C12s cells exposed to 48-hour CM +/- rosiglitazone for 48 hours,
quantified using the Seahorse XF Mito Stress Test, n = 10 per group, except nNF639+rosi =
7 (C). Oil red o image quantification from 4 day differentiated C2C12 cells treated with
48-hour CM for 72 hours, represented as the fraction of each image stained red with oil
red o, n = 8 per group (D).
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Figure 5: Summary of Findings

BC-derived factors induce several physiological changes in target cells in vitro, including
mitochondrial dysfunction, lipid accumulation, and repression of PPAR-mediated
transcription (left). The PPARG agonist Rosiglitazone reverses BC-induced lipid
accumulation but does not reverse mitochondrial dysfunction or the observed
repression of PPAR-mediated transcription (center). Expression of exogenous
PPARG2 in myotubes reverses both BC-induced mitochondrial dysfunction and lipid
accumulation. Figure created using BioRender (right).
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TABLES
Supplementary Table 1: Primers used for qRT-PCR
Forward Primer

Reverse Primer

18s

5’-AATGCTTTCGCTCTGGTCCG

5’-CCTGGATACCGCAGCTAGGA

Cidec

5’-AGCTAGCCCTTTCCCAGAAG

5’-CCTTGTAGCAGTGCAGGTCA

Fabp4

5’-CATCAGCGTAAATGGGGATT

5’-TCGACTTTCCATCCCACTTC

Pparg

5’-TGTGGGGATAAAGCATCAGGC 5’-CCGGCAGTTAAGATCACACCTAT

Slc1a5

5’-CATCACCATCCTGGTCACAG

5’-CCTTCCACGTTGAGGACAGT
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CHAPTER 6: Discussion
Development of and insights from the BC-PDOX model of BC-related fatigue.
Previous animal model systems of CRF have been inadequate for the study of BCrelated fatigue, where women experience a significant degree of fatigue despite
remaining weight stable. The lack of animal model systems that show fatigue in the
absence of atrophy is likely a consequence of the commonly accepted assumption that
the mechanisms underlying muscle fatigue in cancer are the same mechanisms that
underlie muscle atrophy. Our work using CMA is significant as it helps to undermine this
assumption, showing that the increased fatigability seen in two models of BC is likely
not mediated by changes in muscle mass. This finding suggests that the mechanisms
underlying muscle atrophy and fatigue are either independent of one another, or that
fatigue occurs prior to atrophy. In either case, it is quite unlikely that targeting muscle
atrophy would ameliorate fatigue. This fact highlights the importance of identifying
model systems that show increased fatigability in the absence of muscle atrophy, and
quantifying muscle function in addition to overall bodyweight when studying cancer
cachexia.
Our work resulted in the important finding that the PDOX model of BC does recapitulate
the clinically relevant phenotype of increased fatigability in the absence of atrophy, and
we have utilized this model to uncover multiple potential mechanisms underlying this
syndrome. Many of the pathways altered in the skeletal muscle of this model overlap
with those that have been identified as contributors to cancer cachexia. This may
indicate that these pathways underlie CRF that is typically observed in cancer cachexia
rather than the atrophy component of the syndrome. Alternatively, these pathways may
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underlie muscle atrophy, but the relative dysregulation of these pathways in BC is
somehow too minor to allow for a phenotypic change in muscle mass.
Physiologically, our data indicate that slowed calcium release and reuptake in the
PDOX skeletal muscle contributes to the increased fatigability observed, with PDOX
muscle showing altered expression of multiple key regulators of calcium flow, including
calsequestrin 1, calsequestrin 2, and the ryanodine receptor. This same phenotype of
increased fatigability with alterations in calcium handling and increased relaxation times
has been shown in diabetes mellitus (DM) 57, 58. Like women with BC, patients with DM
experience an unusual degree of fatigue that is multi-faceted, poorly understood, and
currently lacks targeted therapies 59. This parallel in muscle physiology with DM
suggests that BC may be inducing an insulin resistant phenotype in skeletal muscle.
This possibility is supported by previous studies showing that women with BC are more
likely than other women to develop DM 60.
The coordinated release and reuptake of calcium in skeletal muscle in response to an
action potential is highly reliant on ATP availability, as calcium reuptake into the
sarcoplasmic reticulum is an ATP-dependent process that must occur to allow for
subsequent muscle contractions 61. The slowing of this process then may reflect a
decrease in ATP availability within muscle cells, which we confirmed by showing a
decreased concentration of ATP in the mitochondria of PDOX-bearing animals’ skeletal
muscle. Decreased ATP availability could be reflective of numerous changes in skeletal
muscle, including decreased storage of high-energy phosphate, decreased production
of ATP by oxidative phosphorylation or glycolytic processes, or increased utilization of
ATP. Our analysis of the skeletal muscle transcriptome in the PDOX mice suggests that
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the production of ATP by oxidative processes may be disrupted due to downregulation
of genes involved in mitochondrial biogenesis and fatty acid metabolism, and the
utilization of ATP may be increased in inflammatory processes. Improving metabolic
function may therefore be a useful cognate therapy to improve ATP availability in
skeletal muscle. One possible avenue to improve metabolic function could be to utilize
agonists of the PPAR family of proteins, which have demonstrated roles in regulating
whole body energy homeostasis 49, have multiple synthetic and endogenous agonists
62

, and are regulators of a significant portion of the genes downregulated in BC-PDOX

skeletal muscle relative to control. PPARγ agonists have been utilized in clinical trials
for BC previously, as it was hypothesized that the agonists would induce terminal
differentiation in BC cells 63, 64. Though no clinical benefit was established in terms of
BC progression in a phase II trial with the PPARγ ligand troglitazone, the study did not
report assessments of body weight, muscle strength, or muscle fatigue, and the drug
was tolerated well by patients 65. Because PPARγ agonists are currently approved for
the treatment of DM due to their action as insulin sensitizers, if insulin resistance is the
underlying phenotype responsible for BC patients’ increased fatigability, PPARγ
agonists or other insulin sensitizing agents could aid in ameliorating CRF by restoring
insulin sensitivity.
Clinical correlates of skeletal muscle molecular profiles in BC.
We found that women with three molecular subtypes of BC, those being ERPR, TN, and
TP BC, exhibit overall similarity in muscular gene expression, with a gene expression
profile that is quite distinct from that observed in women with tumors overexpressing
HER2/neu in the absence of ER and PR. Despite this marked difference in gene
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expression, all subtypes showed similar pathway-level dysregulation, indicating that
treatment methods for muscle fatigue in BC patients may be generalizable across
molecular subtypes of BC. Repression of transcripts involved in several metabolic
pathways, including pathways regulating mitochondrial functions as well as
carbohydrate, lipid, and protein metabolism, was consistently observed across all
subtypes. Additionally, we observed downregulation of electron transport chain (ETC)
proteins in muscle from patients with HER2/neu-overexpressing tumors. As previous
publications have shown that abundance of ETC complex proteins strongly correlates
with skeletal muscle oxidative capacity and mitochondrial density 66, BC patients likely
also have decreased mitochondrial density in their skeletal muscle and decreased
oxidative capacity.
One particularly interesting finding from our work was that the molecular changes
occurring in skeletal muscle in response to BC appear to be relatively independent of
treatment history, indicating that the muscle-intrinsic mechanisms of CRF are not a
response to anti-cancer therapies. This hypothesis is supported by our in vitro
conditioned media experiments where tumor-derived factors directly repressed aerobic
ATP production and PPAR-mediated transcription in differentiated muscle cells.
Additional interesting findings from assessing clinical data against skeletal muscle gene
expression data included the lack of a relationship between gene expression and body
weight change, and the near statistically significant relationship between gene
expression and serum albumin. These findings suggest that skeletal muscle gene
expression changes reported in our work are not reflective of a cachectic process, and
that serum albumin could be a useful biomarker for muscle dysfunction, although
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prospective studies would be required to assess these possibilities. Our laboratory
plans to address this in a new cohort of patients, and the study design is currently under
development.
In vitro modeling of BC-induced skeletal muscle dysfunction
Our in vitro work clearly demonstrates that BC-derived factors can significantly
modulate function of skeletal muscle cells, and that this crosstalk does not require the
BC cells to be treated with any anti-cancer therapies or the involvement of immune or
stromal cells. Rather, miRNAs, exosomes, proteins, or other small molecules could
mediate this crosstalk. This finding importantly contradicts recent reports in other cancer
types, where CM from cancer cells did not induce skeletal muscle mitochondrial deficits
in vitro 67. This contrast suggests that different cancer types induce skeletal muscle
dysfunction via different mechanisms, or perhaps that the small methodological
differences between the two laboratories is responsible for the difference in results.
Muscle fatigue is a mechanistically complicated process and can result from a myriad of
factors. In general though, the underlying ability of muscle maintain force production in
response to stimuli relies upon the muscle’s ability to resynthesize ATP following
stimulus. Our in vivo data clearly demonstrate mitochondrial dysfunction in muscle of
patients with BC and in BC-PDOX mice, which would directly impact the fatigability of
skeletal muscle by reducing the muscle’s ability to maintain adequate high-energy
phosphates required for repeated contractions. Our in vitro data then expand on these
findings and suggest this mitochondrial dysfunction is a direct result of BC-derived
factors. Interestingly, the observed mitochondrial dysfunction is accompanied by
increased intracellular lipid deposition, though these processes appear to be
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mechanistically separate from one another. Intramuscular lipid deposition has also been
reported in many pathologies other than cancer, including type 2 diabetes 68 and
smoking-induced insulin resistance 69. As PPARG expression and transcriptional activity
are associated with insulin resistance 50 and many PPAR transcriptional targets are
mitochondrial lipid transport proteins 70, we propose that alterations in mitochondrial lipid
import may be at least partially responsible for the observed lipid accumulation in
response to BC-derived factors. Future studies should investigate this potential link in
greater detail.
Our development of an in vitro model system to study BC-induced skeletal muscle
dysfunction is significant for several reasons. First, we have reported the first successful
attempt to induce metabolic changes in skeletal muscle in an in vitro conditioned media
system. Additionally, we present the finding that the metabolic effects of BC on skeletal
muscle are at least partially mediated via PPAR signaling pathways. This finding
provides rationale for investigating PPAR agonists to improve quality of life in survivors
of BC, and also provides support for the translational relevance of the in vitro system
given the similarities to phenotypes observed in BC-induced skeletal muscle fatigue in
mouse models of BC and in women with BC.
Limitations and future directions
The most significant limitation in our in vivo work is the fact that our RNA-seq and
proteomic analyses in human subjects did not include any measure of fatigue. Thus, we
cannot say with certainty that the molecular changes observed in skeletal muscle of BC
patients are in fact reflective of increased fatigability. However, our data certainly show
that BC-PDOX mice exhibit higher rates of fatigue, and we also know from current
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literature that the vast majority of women with BC experience CRF. Therefore, it is likely
that the molecular changes occurring in both the BC-PDOX muscle and human muscle
are reflective of the mechanisms underlying fatigue in human patients. Our laboratory is
currently developing a new protocol that will include obtaining subjective and/or
objective measures of fatigue in patients to assess alongside skeletal muscle molecular
changes induced by BC. Once we are certain that our targeted mechanisms are indeed
reflective of CRF, interventional studies targeting these pathways would be appropriate.
A similar limitation is also apparent in our in vitro assays. While our data strongly
support the idea that PPARG activity is somehow involved in the mitochondrial
dysfunction and lipid accumulation induced by BC-derived factors, we cannot say
whether or not these phenotypes are reflective of fatigability in vivo. Mechanistically, it is
reasonable to suppose a causal link between defects in metabolic functions and
fatigability, particularly in light of the fact that both the BC-PDOX mice and BC patients
showed decreased ATP content in their muscle tissue relative to control. However, a
reasonable supposition is still only a supposition, and creative methodologies will be
required to definitively connect metabolic dysfunction in vitro to fatigability in vivo.
Overall conclusions
Our laboratory’s work has culminated in several important findings. First, the
identification of the BC-PDOX model as an appropriate model for studying BC-induced
muscle dysfunction in the absence of cachexia is of paramount importance to the study
of this common and debilitating condition. Targeting muscle dysfunction in BC patients
has the potential to improve the lives of millions of BC survivors, and to potentially
improve overall survival in women undergoing treatments. Further, utilizing RNA-seq
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and proteomic analyses, we show that BC patients’ skeletal muscle exhibits
dysregulation of multiple metabolic pathways regardless of treatment history, molecular
subtype, body composition, or changes in bodyweight, with dysregulation of oxidative
phosphorylation and signaling via the PPAR family of proteins overlapping between all
molecular subtypes of BC and BC-PDOX mice. Dysregulation of these pathways could
explain the significant reduction in ATP content seen in mitochondria and bulk muscle
tissue from BC-PDOX mice and BC patients, respectively. Our in vitro work establishes
an important model system for studying the metabolic effects of BC-derived factors on
differentiated skeletal muscle, shows that BC-derived factors can directly modulate
skeletal muscle function without the involvement of immune or stromal cell mediators,
and shows that signaling via the PPAR family is likely integral to these effects. Overall,
our findings point to significant metabolic dysregulation in skeletal muscle as a main
contributor to the increased fatigability seen in BC-PDOX mice and women with BC,
with these effects being induced directly by BC-derived factors rather than via
immunological mediators or as adverse effects of therapy.
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